Maratha Mandal's vishquas G Hujutan Human Laman Bella Gan Bella Bella Gan Be

Maratha Mandal's

Nathajirao G Halgekar Institute of Dental Sciences & Research Centre, R S No. 47A/2, Near KSRP Ground, Bauxite Road, Belagavi – 590 010 Karnataka, India

Phone: 0831-2477682 Fax: 0831-2479323

Email:mmnghids@gmail.com Website: www.mmdc.edu.in

INDEX

3.3.1

Sl. No	Details
1	Ethical committee members
2	Research publication ethics guidelines
3	Ethical committee minutes of meeting
4	Ethical committee policy booklet

Maratha Mandal's

Nathajirao G. Halgeker Institute of Dental Sciences

& Research Centre.

BELAGAVI

शरीरमाधं खल धर्मसाधनम

Dr. Ramakant Nayak Principal



Nathajirao G Halgekar Institute of Dental Sciences & Research Centre, R S No. 47A/2, Near KSRP Ground, Bauxite Road, Belagavi – 590 010 Karnataka, India

Phone: 0831-2477682 Fax: 0831-2479323 Email:mmnghids@gmail.com Website: www.mmdc.edu.in

3.3.1 Course content and ethical committee members

2016-17 and 2017-18

1	DR. ANJANA BAGEWADI	CHAIRMAN
2	DR. RENUKA AMMANAGI	MEMBER SECRETARY
3	DR. VIKRAM PAI	MEMBER
4	DR.KISHORE BHATT	MEMBER
5	DR. VIJAYLAKSHMI K	MEMBER
6	DR.VINAYAK JOSHI	MEMBER
7	DR. MANOHAR KUGAJI	MEMBER
8	DR. PRAVEEN MANDROLI	MEMBER
9	DR. PREETI KUSUGAL	MEMBER
10	DR. POOJA DESAI	MEMBER
11	DR.RAVI SHIRAHATTI	BIOSTATISTICIAN

Dr. Ramakant Nayak Principal

Nathajirao G Halgekar Institute of Dental Sciences & Research Centre, R S No. 47A/2, Near KSRP Ground, Bauxite Road, Belagavi – 590 010 Karnataka, India

Phone: 0831-2477682 Fax: 0831-2479323 Email:mmnghids@gmail.com Website: www.mmdc.edu.in

2018-19 and 2019-20

COM	POSITION OF ETHICAL C	OMMITTEE 2018-2019
DR.	ANJANA BAGEWADI	CHAIRMAN
DR.	RENUKA AMMANAGI	MEMBER SECRETARY
3	OR. VIKRAM PAI	MEMBER
4 Di	R.KISHORE BHATT	MEMBER
5 DF	VIJAYLAKSHMI K	MEMBER
5 D	R.VINAYAK JOSHI	MEMBER
DR.	MANOHAR KUGAJI	MEMBER
B DR. F	RAVEEN MANDROLI	MEMBER
DR DR	. PREETI KUSUGALimo G. Halo	MEMBER
0 0	DR. POOJA DESAI	MEMBER
1 DR	RAVI SHIRAHATTI LAGAV	BIOSTATISTICIAN

शरीरमाद्य खल धर्मसाधनम

Dr. Ramakent Nayak

Nathajirao G Halgekar Institute of Dental Sciences & Research Centre, R S No. 47A/2, Near KSRP Ground, Bauxite Road, Belagavi – 590 010 Karnataka, India

Phone: 0831-2477682 Fax: 0831-2479323 Email:mmnghids@gmail.com Website: www.mmdc.edu.in

2020-21

1	DR. ANJANA BAGEWADI	CHAIRMAN
2	DR. HARSHADA HALGEKAR	MEMBER SECRETARY
3	DR. RENUKA AMMANAGI	MEMBER
4	DR.RAJENDRA HALLIKERIMATH	MEMBER
5	DR. CHETNA B	MEMBER
6	DR.RANGNATH NAYAK	MEMBER
7	DR. CHANDRASHEKAR. Y	MEMBER
8	DR. PRAVEEN MANDROLI	MEMBER
9	DR. PRACHI SHIVAPUJE 100 G Ha	gekar MEMBER
10	DR. BABU METGUD	MEMBER
11	DR.RAVI SHIRAHATTI ELAGA	BIOSTATISTICIAN

गरीरमाचं खल धर्मसाधनम

Dr. Ramakant Nayak Principal

Maratha Mandal's National Research Comments of Distances a Research Comments and RELAGAVI self-sensitive regularities and qualifications and present the self-sensitive regularities and participations.

Nathajirao G Halgekar Institute of Dental Sciences & Research Centre, R S No. 47A/2, Near KSRP Ground, Bauxite Road, Belagavi – 590 010 Karnataka, India

Phone: 0831-2477682 Fax: 0831-2479323 Email:mmnghids@gmail.com Website: www.mmdc.edu.in

2021-22

1	DR. ANJANA BAGEWADI	CHAIRMAN
2	DR. SANDEEP KATTI	MEMBER SECRETARY
3	DR. RENUKA AMMANAGI	MEMBER
4	DR. HALIKERIMATH	MEMBER
5	DR. VIJAYLAKSHMI K	MEMBER
6	DR.CHANDRASHEKAR .Y	MEMBER
7	DR. CHETANA. B	MEMBER
8	MR. VIJAY MORE	SOCIAL WORKER
9	ADV. YARADAL	LAWYER
10	MRS. ASHA RUTTONJI	HATTER LAYMAN
11	DR.ANURADHA. B	BIOSTATISTICIAN

Dr. Rama ant Nayak
Principal
M.M's. N.G. Halgekar Institute of Dental Sciences
& Research Centre, Belagavi-590010.

Maratha Mandal's Nathajirao G. Halgekar Institute of Dental Sciences and Research Centre, Belagavi

Research publication / presentation ethics guidelines at the Institute

These guidelines are applicable to all the research work carried out at the Institute including main dissertation, term papers, short research, case reports, original articles, reviews and meta-analysis conducted by faculty, Post graduate or undergraduate students at the Institute.

- All the research work conducted in the Institute has to mention in any subsequent publication or presentation the name of the Institute and the concerned department's name in the methods section. Such details also need to be mentioned in description of author affiliations.
- Decision regarding 'First Author'
 - 1. Publications related to main dissertation/ thesis should have PG student as 'First Author' and the staff who has guided the dissertation should be the 'Corresponding Author'. The remaining authors can be choosen based on the substantial contribution to the research and the manuscript.
 - 2. Publications related to Non-dissertation for example, short studies, surveys, case reports, case Scenarios, Reviews, Meta analysis etc can have the first author whoever conceptualized the 'Primary Idea' to do the study or present the finding into a Publication. The Primary Idea can be from staff, PG or UG student or staff of other department.
- ❖ The Institution's name should be as "Maratha Mandal's Nathajirao G. Halgekar Institute of Dental Science & Research Centre, Belagavi."
- ❖ Kindly publish articles in the Journals which are from SCOPUS, Web of Science, UGC care or PUBMED.
- All such completed research must first be submitted to the Head of the department seeking permission for publishing and may proceed with submission only after due approval.
- The Document should contain the final manuscript ready for submission with the title page including authors' names, Institutional affiliations and acknowledgements.
- ❖ The authorship guidelines (See link below) of the ICMJE should be followed for deciding authorship, conflicts of interest and other related issues: http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html
- ❖ The following ICMJE recommended authorship criteria must be strictly adhered to. For being considered as an author, the author must satisfy all the criteria below:
 - Each author should have made "Substantial contributions to the conception or design
 of the work; or the acquisition, analysis, or interpretation of data for the work"; AND
 - Each author should have contributed in "Drafting the work or revising it critically for important intellectual content"; <u>AND</u>
 - o Author shouldcertify "Final approval of the version to be published"; AND

Dr. Ramakant Nayak Principal

1

- Each author must sign an "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved."
- o In addition to being accountable for the parts of the work he or she has done, an author should be able to identify which co-authors are responsible for specific other parts of the work. In addition, authors should have confidence in the integrity of the contributions of their co-authors.
- All who meet the above criteria should be identified as authors. Those who do not meet the authorshipcriteria should be acknowledged appropriately after obtaining written or by email permission for placing their names in acknowledgements.
- ❖ Each post –graduate student and any undergraduate student involved in research should submit the following:
 - O Submit a declaration to the head of the department (of all concerned departments where the research will take place) stating that she has read and will adhere to the institutional guidelines for Publication ethics (As stated in this document) during his tenure at the Institute. Student should also declare that she/he will apply these guidelines while publishing all research conducted in this institution, even after completion of postgraduation and moving to subsequent institutions.
 - On completion of research, submit a declaration that the integrity, originality, truthfulness and authenticity of data were duly ensured to while collecting and analyzing data. The student also needs to name one person from the Institute (with most substantial contribution to the particular work like Guide or co-guide) as "Corresponding author" for that research work for use in subsequent submission for publication.
- ❖ The institution holds the authority to take disciplinary action if any of the aforementioned aspects are not followed. Such disciplinary action may involve informing the concerned journal editor for retraction or informing the University or Council for further disciplinary action.
- All the research work conducted in the Institute has to mention in any subsequent publication or presentation the name of the Institute and the concerned department's name in the methods section. Such details also need to be mentioned in description of author affiliations.

Dr. Ramakant Nayak
Principal
M.M's. N.G. Halgekar Institute of Dental Sciences
& Research Centre, Belagavi-590010.

Student declaration form


(To be submitted to the HOD of departments where the research is being carried out)

- ❖ I have read and am aware of the publication ethics guidelines of the Institute and declare that I will adhere to it during my tenure here. I will also be liable to apply those guidelines to all the research carried out in this Institute even if subsequent publication / presentation is made after I leave the Institution after my post-graduation.
- ❖ I will adhere to and will strictly follow the authorship guidelines (See link below) of the ICMJE for deciding authorship, conflicts of interest and other related issues: http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html
- ❖ I will also adhere to all the research guidelines issued by ICMR and any such competent authority of our nation or state.
- All those who meet the authorship criteria will be identified as authors. Those who helped me with research but do not meet the authorship criteria will be acknowledged appropriately after obtaining written or by email permission for placing their names in acknowledgements. This includes the data processing work, data analysis carried out inside or outside of the Institute.
- ❖ I shall NOT include anyone as author who has NOT substantially contributed to the manuscript as stated in the authorship criteria.
- ❖ I will assure the integrity, originality, truthfulness and authenticity of data collecting and analyzing in my research.
- ❖ I shall name one person from the Institute (with most substantial contribution to the particular work like Guide or co-guide) as "Corresponding author" for that research work for use in subsequent submission for publication.
- On completion of my research, I shall submit a document containing the final manuscript ready for submission with the title page including authors' names, institutional affiliations and acknowledgements.
- For my research work conducted in the Institute, I will mention in any subsequent publication or presentation the name of the Institute and the concerned department's name and names of all substantial contributors in the methods section and affiliations of such presentations/ publications.
- I hold myself accountable for all the above.
- ❖ I know that the institution holds the authority to take disciplinary action if any of the aforementioned aspects are not followed. Such disciplinary action may involve informing the concerned journal editor for retraction or informing the University or Council for further disciplinary action.

Signature

Name of the student and department name

Dr. Ramakant Nayak Principal M.M's. N.G. Halgekar Institute of Dental Sciences & Research Centre, Belagavi-590010.



Edward Committee Meeting to discuss Research Gronts applied for PGUHS Bengalum for the year 2017-18. All the committee members one requisted to attend the meeting at 9.30 a.m 09 07/07/17 at HOD Chamber, Dept of OMDR. 1 Dr Kishore Bhat Dr Proven Mondrolli Dr Vijaylakstimi K Dr Viksom Pai Dr Rasi Shir hetti kindly award Dr Poceti Kusugal Dr Pooja Desci Mr. Manchan & Kugaji Dr. Ramakant Nayak M.M's. N.G. Halgekar Institute of Dental Sciences & Research Centre, Belagavi-590010.

31/07/2017
Phical Committee Meeting In dec 15 Proces
Chical Committee Meeting to descuss Research (Proposal)
All the committee members are requested to
3107 2017 of weeting and 11.30 am co
31/07/2017 at NOD Chamber, Dept of OMDER
OD Kishove Bhace luly
(2) Proveed Mondoodle
3 Dr Vijaykokolimi K.
(5) Dr. Vikorum Pai 1557
3 D. Ravi Shirhatti
Dr Poceta Kusugal Just
Dr Poceti Kusugal Dr Posja Desai. Mv. Manshar S. Kuyaji Munji
Wing
Of collective decision was made to write a letter to the Principal's office to depute
letter to the Principal's office to depute
a member (stuff) to IRB to the position
Vacated by Dr Vinayak Joshi
Desearch Committee which was
the Research Committee which was
headed by Dr Vinayak Josus wion
headed by Dr vinayak Josha wion the consent of higher authority.
(2) The marks to want do
3) The members went drovinger Various Deserver proposals Submitted to the Committee.
Consisted to the
Committee.
Lamba & Only De Dy Kirous
a UG Pescarch Topic by Kirran Lamba & Onker Pawas was approved without any Changes.
b) Research Proposal by Dr Manisha
Deserver Proposal by Dr Manisha Mesekar was approved without cryper
Dr. Ramakant Najan
Principal Principal Sciences
M.M's. N.G. Halgekar Matthews. 8. Research Centre, Belagavi-590010.

De Sujadua
Olleseason proposal by Dr Syjadia
City of Color
· To make it more evidence based
. To onche it more voidence basen
4 to have logical explanation
The changes will be conveyed to the
Staff. 10
4) A letter/circular doon Etwical
Committee to be Eulowithed Selt to
all the departments to Submit the
proposals to the committee well is advance of the deadlone so as
advance of the deadline so as
got time to committee to some to
the proposals proposely.
5) The Minor Reserver Proposeds to be
The man is a second
Contacted in case of need.
Dr Reruka Ammenagi
John Manago
Subcommottee,
Dr Romba A
The state of the s
2) Do Vijaylakslinie K
3) Dr Proween M
4) Dr Rasi 5
Dr. Ramakant Nayak
M.M's, N.G. Halgekar Institute of Dental Sciences & Research Centre, Belagavi-590010.



Nathajirao G Halgekar Institute of Dental Sciences & Research Centre, R S No. 47A/2, Near KSRP Ground, Bauxite Road, Belagavi – 590 010

Karnataka, India

Phone: 0831-2477682 Fax: 0831-2479323

Email:mmnghids@gmail.com Website: www.mmdc.edu.in

Ref.No.MM/BDS/MDS/2017-18/ 1014

Date: 08/09/2017

INSTITUTIONAL REVIEW BOARD

CIRCULAR

The Institutional Review board (IRB) of the college has scheduled the PG dissertation synopsis presentation for I MDS on 24th and 25th October at 9:30 am (timing 9:30 am onwards).

All PG departments are requested to go through the following guidelines

- All Postgraduate students should submit the hard copy of their dissertation synopsis to Dr. Renuka Ammanagi on or before 17th October 2017.
- 2) All the HOD's, PG guides & Co-guides and IRB Committee members are requested to compulsorily attend the entire presentation on both the days.
- 3) Time for power point presentation should not exceed 8 min followed by discussion.(Review of literature to be skipped)
- Changes recommended should be incorporated and submitted to the committee on or before 02-11-2017.
- 5) For information on ethical guidelines PG's are directed to refer WHO consortium and ICMR guidelines for ethics in conducting biomedical research.
- 6) Department of OMDR, Prosthodontics and Periodontics will have their presentations on 24th and Department of Pedodontics, Conservative and Orthodontics will have it on 25th.

Copy to:-

1) Principals office

2) Dept of Oral Medicine

3) Dept of Prosthodontics

4) Dept of Periodontics

5) Dept of Pedodontics

6) Dept of Conservative

7) Dept of Orthodontics

8) IRB Members

whit to note

289/17

glalm

Dr. Ramekant Nayak Principal I.M.'s N G Halgekar Institute of Dental Scien & Research Gentre, Belgaum-590010

✓ Dr. Ramakant Mayak Principal

PG Synop Sis Breseterson Meeting os conducted to 23/10/2017 M.M's. N.G. Halgekar Institute of Dental Sciences & Research Centre, Belagavi-590010. Characolity PL. 01. 27 M 4/10/12/20/17 Dr. Raffakant Nayak 4 Principal to wellowe Power Mendon Ozeni Surrhett Mr. Marchan S. Jugaii Druber American Foreto Kusugal Wilay aleston 1 Fetingal Committee Dr Poota Desai Vikosen Per O Dr Kishore Blue to be held discuss tre Poola 2017

(1) Dr Anjana Bayewadi

(2) Mr Vijay More

(3) Mr Vinesh Yardal Adwinte Medial

(4) Dr Kishore Bhat.

(5) Dr Praweer Mandroll?

(5) Dr Vijaylakshini. k.

(6) Dr Vijaylakshini. k.

(7) Dr Paw? Shirrhatti

(8) Dr Vikraor Pai

(9) Dr Preedii Kusugal Philiphi

(10) Dr Pooja Desai.

(11) Dr Peruka Ammanaga Mry.

(11) Dr Renuka Ammanaga My.

(12) My. Manchar S. Jangayi My.

Dr. Rama Hant Nayak
Principal

M.M's. N.G. Halgekar Institute of Dental Sciences
& Research Centre, Belagavi-590010.

	20/12/2017
of IRB to discuss of	of the subcommittee
of IRB to discuss of	a few sesence
proposade submitted la	o de committee.
P	4
Reseased proposeds were Su Students,	buitted by following
O Dr Stimute Perradkar	
3 Dr Madurkar Nayaka	
(3) Dr Yashashree Pausaste	
(Dr Nikita Burde	
5 Dr Dr Neha Nacionce	
1.7. 1. 4	1 Succested
West duringer the Dooposals	4 Suggested
To ded consul form	
# To me of two the Surce	of samplel. te
Ou bollowing menbess were OD- Ravi Surouatti	Presut
OD- Rusi Sura watti	
	AM-
(3) Dr vijaylakshmi K	
3 D. Renden Honoragi.	my.
	\h_
6 Mr. Marchan S. Kugaji	Wint:
6 or vium lai	Reben
	len
	Dr. Ramakant Nayak
	M.M's. N.G. Halgekar Institute of Dental Sciences & Research Centre, Belagavi-590010.

A meeting was called at the Subcommittee of TPB to discuss the orsarch proposals
Submitted by the various students & also
a PhD condidate.

Following & Studies / PhD Condidute Submitted
tre proposals.

Dr Sneha Gade
Dr Swetalin Das
Dr Porabhadeep Kour

Da Madeura MG.

The proposals were Studied at length & were discussed for the educal TSSLes.

All the Studies had the Intermed consist horm

The committee approved all the four proposals with more changes which was conveyed to the students.

a Dr Parasees Mentrole

Dr vijaylakstini K.

(3) Dor Remba Annonago

(9) Mr. Mandras S. Kugaji

3 or Vikcom. low

\$ Remarks again to the St

Went.

Vekon.

Dr. Ramakant Wayak
Principal
M.M's. N.G. Halgekar Institute of Dental Sciences
& Research Centre, Belagavi-590010.

24/2/18-
The Following committee members (Subcommittee) are requested to attend a meeting or
OD- Vijaylakshani K. Off
Dr Proveer Kuman M (Marchael)
3 D- Pavi Surhatti.
Discussed Dr Sheetal Kubsad's PhD Synopsis.
Suggested Corrector,
1) Methodology 4 Objectures to be modified.
(2) Consent to be done in local larguages.
3) TO Re-Submit one Consected
COPY.
De LENUKA ANGGOTAGII
() During
fm
Dr. Ramlakant Nayak Principal M.M's. N.G. Halgekar Institute of Dental Sciences & Research Centre, Belagavi-590010.

The Following Committee members are requested
to attend a meeting on 10/04/18 at 10.00 m.
in OMDR Dept.
Q. Dr Proven Mandrallin Q (Wa. 4.18
(2) Dr Raw Shir helle In 94115.
3 Dr Vijerlakorni K Q Ff 14/18
De Procedui Kusugal Punggil
(5) D- Popin Desai. Absent.
Da Pozia Desai. Absent. (1) Mr. Marchon S. Kugaji Wuf.
Discussed 3 Topics.
Dr Sneetal's PhD topic.
Minor corrections to Wortha
Minor corrections 10 Wording Objectives.
Conveyed to Dr Sheetal.
2). UG Research Project -> Survey among Dutal Practoners.
among Dutal Proachoners
Modified Que Stronzaine.
Suggested to maintain Confidentiality (To senoue manne)
(To serioue a name)
TO & Re-Submit offer dong carages
(3) Dr Sacreta -> 5 host study.
· To modily tetle
· To elaborate mediadalogy
· To change Startistical fests,
· To add Consulton to local
1-25- 0.085
Conveyed are Changes to her a to Re-sumit
Y

Dr. Ramakant Nayak Principal M.M's. N.G. Halgekar Institute of Dental Sciences & Research Centre, Belagavi-590010.

tossous in OSMF - A pilat study

PI - Da Ashina K Chi

Dr. Ramakart Nayak
Principal
M.M's. N.G. Halgekar Institute of Dental Sciences

Re studies were evaluated for estudias
Concesos.
Dr Hamerda Bee was asked to Change
dre title for In-vitro to En-viva
as he 135 ne samples were taken
boon pertreits.
Tant Navak
Dr. Ramakant Nayak Principal Principal Sciences
M.M.s. N.G. Halgekar Institute of Dental Sciences 8. Research Centre, Belagavi-590010.
1.72

The Synopses Presentation of I'st MDS students
has been planned a arranged on 16/10/18 ?7
Collège auditorium Por de following Studies.
O Dr Umesh Bhosle
@ Dr Modur Nikam (Pedonatics
(a) Dr. Maduri Nikam (Pedonatics (b) Dr. Akhaya Lak
@ Dr Agrison Prodeep Periodochics
(F) D- S. Rakendur - Orosal Persholology.
The above mendlined Studiets are attending
Conference Or are having some personal issues
Conference Or are having some personal issues hence can not attend on 25th 26th october 2019.
The following Committee members are Present.
1) Dr Anjara Bagewadi Da (2) Dr Renakat payak. fing (3) Dr Poraves Mondrollo. Mendril
Dr Ranakart Dayak.
3 Dr Poravees Mondrollo. Mender ?
4 Dr Vijaylakshmi K.
To Dr Chendrashekhar Jangal Cyny
9 Dr Porcesi kusugal. July
Dr Priesi kusugal. Jud 8 Dr Vikoun Peni. Jula 9 pr keshae Bhuer (ahes
(a) on histar shul- (ches
(1) Mr. Manohar S. Lugaji Ches
(II) ear Manchay (t.
myg,
The Study proposals were discussed in longth
4 the consections were told to be students.
Dr Akshaya was asked to prepare a simetable
for follow-up
De Adurace was asked to consider
De Adurace was asked to consider Changing Objectives of de Study.
Dr. Ramakant Nayak Principal
M.M's. N.G. Halgekar Institute of Dental Sciences & Research Centre, Belagavi-590010.

1 St MDS Students Synopsis Presentation.

Following committee members cuterded de PG Sypopsis Presentation. The research proposals were discussed.
In length 4 de suggestions were conveyed to the Students. Pas were asked to do modifications in the Synopses a to row submit 5th November
(1) Dr Anjana Bagewadi Opai
@ Mr Vijay More
(F) Dr Ramakent Nayak. Fr. L. (F) Dr Kishore Bhat
5 Dr Peravees Mendrole Whall
@ Dr Vijaylaksuni K. Opp
7 Da Vikorem Perè Hom
1 Dr Rave Shorhattie for.
(9) Der Pocestie kusuged gud.
(6) Der Pooja Desue poo adjolie
(1) Des Remba Amenago. At
(12) Dr Madher, Pyjar Just
(3) Dr Viraj Patil.
(19) Dr Sheetal K. Abrild 1.

(45) Mr. Manobar S. Jugaji

Dr. Ramakant Nayak
Principal
M.M's. N.G. Halgekar Institute of Dental Sciences
& Research Centre, Belagavi-599010.


(15) Dr. Vecrendra UPP15)
To Dr Procede Astago
(A) D- Zanon Ruttonji
(18) DR RB. Hallikeminath
19. R. Pallari. Gopeshetli
20. Dr. Puhpa. S. P
21 Dr Hemant. 7. Vagaroli http://8
22 Mr. Marchan S. Juggi
SULSEN STATE OF THE
Dr. Ramakant Nayak Principal
M.M's. N.G. Halgekar Institute of Dental Sc & Research Centre, Belagavi-590010
M.M's. N.G. Halgekar Institute of Dental Sc & Research Centre, Belagavi-590010
M.M's. N.G. Halgekar Institute of Dental Sc & Research Centre, Belagavi-590010
M.M's. N.G. Halgekar Institute of Dental Sc & Research Centre, Belagavi-590010
& Research Centre, Belagavi-590010
& Research Centre, Belagavi-590010
& Research Centre, Belagavi-590010
& Research Centre, Belagavi-590010

Principal

M.M's. N.G. Halgekar Institute of Dental Sciences
& Research Centre, Belagavi-590010.

I MOS SYNOPSIS PRESENTATION I MDS-Post graduate students presented synopsis from the dept. of Outlodontis. I'm tront of thical committee member thical committee members. Suggest modifications conveyed were asked tollowing committee vere frese Anjana Bagewadd De Renuka Anmanagi Me Unesh Yardal 5) De Praveen Mandeoli De Ravi Shirabathi 4) De Aquati Nayak m. 1) Dr Purhpa S. Pudakalkatti Velen 9) Dr. Vilvam. Pa. 10) De Madhu Prijas HILLIAN CHARLESTOCK 12) A. Sheetal Sandy 121 Au suvar re latil texis

A meeting of Subcommittee called to 10/12/18.
discuss the following Agenda.
O To design & propose protocole for Warner for Consert form in cases of setrospective
Consert form in cases of actrospective
a) To go ourruge sa research proposals Submitted by Conservative Pa's (Short study).
Sile of Outstage St. Shoot study
Sibmitted by Consessation fas ().
· Research Proposal by Dr Nikita Kapshe
· Research Proposal by Dr Nikita Kapshe PG Conservance - To follow ICMR Consent
form & to include all ource languages (kannada, pranadui)
(kanada, Maradii)
· Studies wurde have less duas animal
orsk like octoospective studies interviews - etc.
1) Dr. Viculalisting Rotoushoffe AMM
1) Dr Vijaylakshing Kotoushotte Duf
2 Dr Rave Survalutti -
(3) Pr Romba Amanagi - Durch.
(5) Mr. Manchor S. Jangaji Quyi
6
(3) or vincen Pan Vilay
i hv
Dr. Ramakani Nayak Principal
M.M's. N.G. Halgekar Institute of Dental Sciences & Research Centre, Belagavi-590010.



A meeding of subcommittee to discuss are following research proposeds on 23/2/19 @ Effect of Cold Salene irrigation on Post operative pain - A RCT P. I -> Dr Satyam Tarswel. Co-sections told by the committee were Jucosposanted. (3) Assessment of animicrobial activity Of osussaya Koenegij on Periodortal Pertrogens - An M-viloro Study PI -> Dr Streshma Padmanabhan (3) Comparative evaluation of collection, Cultivation a identification of not yet Cultilated orall anaposite bacterice by using innovative cutore methods. PI -DP Preedui Kusugal ICHR grant Proposon were communicated 4 de sone are incorporated in the amended copy (1) Ex-UND Culture of Oral Kesabinocytes using Direct explant cell cultive -technique PI - Dr Vijaylaksling Kotsushetti (3) Comparative evaluation of smear layer removal effective of 2.5 y. Sodium hypochlowite Mixed with 187. HEBP using two different Transgator techniques - A SEM Study PIJD- Bheemoreday UNEL Reddy. Dr. Ramakant Nayak

above mershaned research proposults.	e Ger	Dans Swrheetti	Signey laksture kotsustretti	o Reulus Bonneway" ()	. Vibram Car	Dr. Ramakant Nayak	M.M.S. N.G. Halgekar Institute of Dental Sciences & Research Centre, Belagavi-590010,	
The above of was	6	OD. Ren	De Cita	(3) Dr (C)	a Br. Ville			

(18)

A Subcommittee Meeting is called to discuss the following sesemen Proposals which there been Submitted to the Research Committee.

De A reserren proposal title "Isolation Identification of Characterisation of Aggretisater actiony come consistent from patients with aggressive periodophis" submitted by Dr Kishore Bhat. The selection of patients a sample collection will be done at Kaminene Institute of Delack Services - Andhra Providesh. The Laboratory Procedures to will be corrised one in CRL MMNGH IDS. For the lab procedures are educated Confirmation of the confirmation o

2) A research proposal submitted
by Dr Swappali B Ghumare was


avaluated Title - A Kaleidoscopie vision

The following correction convention

Communicated.


- does not reflect de study design.
 - . Objectues need to be refuranced
 - · Methodology need to be more
 - Stutistic -> Sample Size estimates
 - Studies has been combined / In

Dr. Ramakaht Nayak Principal



121113

TS+ MDS SYNOPSIS PRESENTATION. BATCH - 2019-2022 I'st MDs / Post Graduate Students presented their Synopses for the dissertation to me Edwical Committee. Suggestions of modifications were conveyed to the Students of they were asked to Re-submit the same by 18th Nov 2019 The following Committee members, PG quides a Faculty members were present. Da 12/11/2019 O Dr Anjana Bagewadi Dr Kishore Bheet Dr Rumakout Nayak 4 Mar Vijay More Mr Voresh Yardal Dr Vijaylakshnio K (9 Dr Vikron Pai Prest. (8) Dr Preedw kusugal 3 Dr Rout Shor hall! 10 Dr Power Mandrali (1) Dr. Shutal Kubared Thulong 1 De Madhu Pyas JAR Dr. Ramakant Nayak 13) Dr Hemane Vagaralo M.M's. N.G. Halgekar Institute of Dental Sciences & Research Centre, Belagavi-590010





TSE MDS STNOPSIS PRESENTATION.
11/11/11/11
The 5ynopses on presentation condinited
Department of Penodines Possibled and es
a Predodonties Pais to presented the
5 yr cpsis
Suggestions a modifications were conveyed to
the PG-S.
Following members attended the meeting
OD- Prjera Bugewadi Do
@ Tam vijang more proper
1 ml
(3) Mr Vimesh Yardal
(4) Dr Kishore Black
(3) Dr orong Puble
W. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.
6 Dr Poweer M. White
$\int_{-\infty}^{\infty}$
@ Dr Rang Shirmon MS
a and
@ Da Vijalakshing Off
(5) Dr Procost Knoughe guel
To Dr Remaked Novak, fine
(1) Dr Rongonada Payak. 13/11/19
1. Stufe)
D'or Ajaytumar Norphe Mygnospa Int Novak
Domakant Nayak
13) DR K B 7 acm (em moth)
Roles 19 Research Centre, Belagavi-590010
& Research Centre, 2013

Meeting of Subcommittee to Discuss Reseased Proposals.

Two reseasen Proposals are Submitted by Mar Vijay Kumberr Presearen afficer CRL The ocseanch Posoposals were discussed on length & the Cardidate was asked to Submit the copy of a letter Submitted by wanto the Institute to the 5 DM College for sample collection CRL will be conducting The vitro procedures of cancer cell Line (oral & head & neck concer) preparation The reserver Proposels by a Pa DR ATHUL CHANDRA was discussed. The change in Tithe for Dr Deepe Babis is declaration of Submission of Old Certificate. 1 Dr vijaylakstino k

1) Dr Vijerylakshani k 1960 2) Dr Rawi S Jahla (3) Dr Renden Ammanagi ((5) Mr. Marohar S. Kugaji Muf.

Dr. Ramakant Nayak Principal The research and Ethical Committee meeting will be held on 9.1.2020 at 10.30am to discuss a research project for ICMR grant.

All the members are requested to make it Consinient to attend the same. The meeting will be held at Seminar room, Department of Periodon tology.

Member	Signature 0's or lun
1. Dr. Ranganath Nayak	
2. Dr. Renuka Ammanagi	Om 6/1/2020
3. Dr. Pravcenkumar Mandroli	MARINA
4. Dr. Rais Shrrahatti	W.1.19.
5. Dr. Rajendra Hallikerimath	
6. Dr. Chandrashekar Yavagal	m/som
7. Dr. Prachi Shirpuje	Aught 2020
8. Dr. Babe Metgud	A ghtzord
9. Dr. Chetana Bogar	Sec 1 2020

Dr. Harshada Hulyekar

The synoposis for research project is not yet submitted. Or Madha Pajar has informed that the synopsy will be submitted by 12. worm and has reguested to postpone the me

Dr. Ramakant Nayak

meeting. So, the meeting will be held at 1.30 pm on 9.1.2020.	-					
m 4.1.2020,						
my 1						
	-					
9.1.2020	_					
9.50 am.						
Mal	-					
Meeting was conducted at 1.30pm. The following points were discussed						
Seperate outward numbers to be given for ethical						
Charance certificate issued for mos/BDS/Staff research						
research						
. Sub- committee can be formed to discuss user research projects.						
The research project submitted by CRI of						
conservate dertistry						
for exceptions Characterization fixed tion 12th Line	_					
Exadente Broth Madels						
- Statistical tests for all research variables should be						
	_					
- Details of laser to that will be used should be written.						
a. ad	_					
- Details of equipments used - Technicals, manufacturer						
and country to be mentioned	BYTH TRANSPORT					
- Torbidity strong standard to be mentioned	-					
3	_					
Meeting was attended by - 1 13.	-					
1. Dr. Renaka A.						
2. Dr. Praveenkymar M. Ma.1.20.						
3. Dr. Ravi S. drejuno						
4. Dr. Rajondra H. 4381	April 100					
5 Dr. Chandra Shekar Y. pr/Sangre 112020	and a second of					
Machi Regolie	V					
Marshada 10						
	nt Nayal					
Dr. Prachi Pro Harshada	-					

	a) be
The research and Ethical	a 30 cm to discuss short
Chile remarks are at	4.30am to discuss short
Dr. Ryladon)	abmitted by PGs, CD1. Rojesh and
The agenda for meeting in	also to discuss about
regulation of Ethical com	mille with Mabaral ethics
Committee Registry too Biome	died and Health research, with
The meeting will be head	at seminar room, Dept of
Periodontelogy.	at seminar room, Dept of
1,14,15	
Member 1. Dr. Ranganath Nayak	Signature
1. Dr. Ranganath Nayall	03/04/200
2 Dr. Reneka Ammanaji	Our of
	1 1 Ala / hust AF
3. Dr. Pravenkumas Mandra	Municipalion)
	^
4. Dr. Ravi Shirahatti	W. 0
5 Dr. Rajendra Hallikenmatt	
> W. Ragerord outer Kerning	
6. Dr. Chandra shekhar Yourge	al mysan (UNAVAILAGE)
7. Dr. Prachi Skrupuje	(Lucius
8- Dr. Baba Metgad.	_
	cm 3990
9. D. Chetuna Bogan.	Orte (
A Section of the sect	JUS 3.02.200
	Dr. Harshada Halgekar
	and the same of th
	W
	Dr. Ramakant Nayak Principal
	M.M's. N.G. Halgekar Institute of Dental Sciences & Research Centre, Belagavi-500010.

(1) Committee should Include Legal expect, social scientist, hard copy format do members secondation and Soft copy should be sent to id-mail to IEC. 3 member secondary will forward the overarch proposal Should review the procearch proposal within I days (B) Need for baining audit committee to audit the work do all the co. I. &c members via email. members and outly at earliest.

(3) Seprente file / folder will be maintain for each

(4) Seprente file / folder will be maintain for each

(4) Seprente file / folder will be of IEC was disturted. D. Malliberimeth will provide a Provided All research proposals will be soved (10) updated CV of all IEC members should be @ The proposal should be submitted in the format in which ethical committee is andited. Layman and Pharmacist. in the hard disk. Submitted .

Wayn 3/2/2020 G GIR 9080 (12/2000) 4. Dr. Rayendre . Hall Kerimath -Meeting was altended by: 1. Dr. Rangarath. Nayak -2 Dr. Rende Ammanyi -3. Dr. Ravi. Shirahalti -6. Dr. Chetana. Bogar

M.M's. N.G. Halgekar Institute of Dental Sciences & Research Centre, Belagavi-590010

Jul 72.20

the research and Ethical held on 2.3.2020 at	9:30 am to discuss research
proposals for short studies	submitted by P.G. students.
All the members are requ	usted to make it comment to
afters the same. The m	seeling will be held at
conference room in the a	ollege office
Membas	Sign
1- Dr. Rangonath M.	-1 Solutions
2. Dr. Romenka A.	Come 8
3- Dr. Praveen Kurae M.	Mark Eminar at 9.30 (m)
4. Dr. Rai S.	26/02/20
5. Dr. Rojendea 29.	3/26/02/20
6. Dr. Chandrashekhar Y.	
7. Dr Prachi S.	26 (2) 2020
8. Dr. Babe Met gud	
9. Dr. Chetana Bogas.	28/2/20
	dry 26.2.2020
	Dr. Harshade H.
	Mombee Secretary

Dr. Ramakant Nayak Principal M.M's, N.G. Halgekar Institute of Dental Sciences & Research Centre, Belagavi-590010. Meeting was conducted at 9.30 am in the conference room of the college office. Total 7 members were present for the meeting. The following points were discussed.

- It was decided that the scentary is authorized to request for relevant missing documents and information as per comments largestions of individual SER members before the study is revered in the ZEC meeting.
- depulsional informing than that Ethical clearance by

 JEC is mandatory before commercement of any strong!

 Tescarch. The CRL has to be informed to not

 accept any request with or commerce the strong in the ethical clearance certified.
- 3. Member Scenetary informed that auditing of
 Ethnul committee is not mandatory for registration
 for IEC with Health ministry DMR Member secretary
 had in Eliphonic conversation with help center at
 natik-gov.in.
- 4. The scentary had discussed with the Principal st on T.2.2020 regardry training of SEC members. The Principal suggested that Dr. Subarry Pay, Jenk, Belgui could be contacted through Dr. Kishace Bhut, CRL.
- 5. Annuar to be sent to all the departments that the stringful innestigators of research proposally submitted to IEC should be present call be called for during IEC meeting along with the study details, and replied to queries sent by IEC before,

Dr. Ramakant Nayak Principal M.M's. N.G. Halgekar Institute of Dental Sciences & Research Centre, Belagavi-590010.

3165.

6. The research proposal should be corrections after the meeting. The be highlighted	submitted with
corrective after the meeting. The	muching week sho
La Assista	
be highly here	
	The state of the s
7. 7 research proposal were discussed suggestives gues according to the attack	and comments
Suggestive gues according to the attack	hmut.
3 0 5	
M- \	
Members	
Do Rayaneth M. Orbis w	
0 05	
2. Dr. Renuka A. (Yours	
Dr. Rangemeth M. Johns for South of the State of the Stat	
De Res View Million 123	
B. Dor Pravan Kunas (Which of h)	
4, Dr Rai S,	
S. Dr. Hallikeemath	
C. Dr. Chetana B. (mari	
Charles D.	
. Dr. Harshede H, Jug	
Dr. Prachi! K Awaliy	
El superel	phu
	Dr. Ramakant Nayak
M.M's. N	Principal I.G. Halgekar Institute of Dental Sciences
8	Research Centre, Belagavi-590010.

the research and Ethical committee meeting will be held on 13.3.2020 at 9.30am, at conference
held on 13.3.2020 at 9.30 am, at conference
orige office. It the members are
regrested to make it convinient to attend the same,
Members. Sign. 1. Dr. Ranganath H. Christ Mill of U. 2. Dr. Renuka A. 3. Dr. Praveenkumae M. Phillips.
CAMPATAN JU
1. Dr. Rongmath H. CANNER MICE TIL
111.031.0
2. Dr. Renuka A.
2 2 2 2
3. Dr. Praveenkumae M. Phull 11.03.
4. Dr. Ravi s.
S. D. P. J. H.
5. Dr. Rajendra H.
6. Dr. Chandra Shekhar Y.
7 D. P. V.
7. Dr. Prachi S. — Ayacii 11/3/2020
[13]202
8. Dr. Baby Metgud
109
9. Dr. Chetana Bogar, Comba 11/3/2020
try
Dr. Harshada H.
Member Secretury
The secretary,
Dr. Ramakant Nayak Principal
M M's N G. Halgekar Institute of Dental Sciences
GA Centre, Bolagary Leonato

and the state of the second se	
The research and edical com	mitte meeting will be held
on 16th sept 2020 at 10	oo am, at interence
room in the college office. All	the members are requested
to make it compaint to able	at the same Revised smoosis
of short studies a bounded to able	il I drumd
of short stedies submitted by Ples	will be disable.
Members:	dign
1. Dr. Ranganath N.	14/3/20 14/3/20
	0 8 12 20
2. Dr. Renuka A.	W 14/3
	AL AD
2 - Dr. Praven Kumer M.	Mark 2,20
4. Dr. Ravis.	000
	16k1 Duty
5. Dr. Rajendra 21.	16k/20 000 16k/20 puty
3	
6. D. Chandrashelchar Y. Con	leare) UMM_15/01/20
	15/01/20
7. Dr. Prach, S.	
	leave
8. Dr. Babu Metgud	
	1 - 2
9. Dr. Chetona Bugar.	cm/300 20 20
	14/9/2000
	Dr. Harshade 4.
The second secon	
The proposed and the control of the	member secretary
The state of the s	Dr. Ramakant Nayak
	Principal
	M.M's. N.G. Halgekar Institute of Dental Sciences & Research Centre, Belagavi-590010.

Meeting was conducted at 10-am in the conference rooms of college office. Total 6 members attended the meeting. The following points were discussed.

O Received synopsis and correction submitted by post-graduate and undergraduate students were discussed. (3 studies)

- Dr. Ortone Bogae had requested the IEC in uniting on 12.3.20 20 regardy need for the publication and athour authorship guidelines for various research work that was corried out at the synthete.
- A downat regarding 'Research publication [presentation ethics quidling at the Institute was discussion and few suggestions were given.

 college name can be written in materials and methods section of article if the Journal permits doing so.
- Diciplinary Action would be taken by IEC.
 - For publications of care reports the schedult along with the staff who guided (monitored the care will be main authors.
 - Guide will be the corresponding author for publication of their discortation work.

a staff member will have to inform the ethical committee in writing if any unethical research is done and noted by the staff in the department I tretitive

Attended by
Dr. Rangareth M.

Dr. Reneka A.

Dr. Harshade M. Jr.

Dr. Prace: K. Bence Y.

Dr. Rajendea M. Bill.

Dr. Ramakant Nayak Principal M.M's. N.G. Halgekar Institute of Dental Sciences & Research Centre, Belagavi-590010.

	with meeting will be
The research and estimal	t inference rum
held on 19 oct 2000 at 1	o over a ted to
in the college office All the	men port our
make it constituted to actino	
Short studies submitted by	Plas will be discussed.
the state of the s	
Menhors.	and the same of th
Dr. Langaralt H.	
3	(Stall of)
De Renuka A.	100
	1.8/10/10 2° 2° 2° 2° 2° 2° 2° 2° 2° 2° 2° 2° 2°
D. Pravier Kimas M.	10°2
	1 (97)
Dr Ravi S	JE 10/20
Dr. Rajes dra H.	BU 16/10/20
7. 13.	
Dr. Chandra Shekhar Y.	lcane
);	
Dr. Prachi s.	Amuci
35	4
Dr. Baly Metgud.	_
	1.2
Dr. Chetana B.	1.4584
3, 5,5,5	ine
	Dr. Harshade H.
	Member Secretary
	that it is the
	the control of the same property and the control of
	A CONTRACTOR OF THE PARTY OF TH
Management of the state of the	the
Jo vanne	Dr. Ramakant Nayak Pvincipal
And the same of th	W.M.S. N.G. Halgekar Institute of Dental Sciences
	& Research Centre, Belagavi-590010.

The research and ethical	committee meeting ares
	n the conference room in college
	abore attended the meeting.
The following points were	
(2) Short shidy synapsis sol revened and og suggestions	mitted by Dr. Bhakeli was
7 0	3
A \ \ \ \ \	
Alkinded by	
- Dr. Halli kegmith	El
	7
- Dr. Penila A.	(Vm Y
- Dr frances Kumal M.	MMM 19.1020
	14. 00.
D. Ravi S.	446
	18/10/20
Dr Haush de H.	ml
Dr. practi K	Stacing
,	C. March
	and the same of th
	len
The Remokan State Communication of the Communicatio	the second specification where the second is second to the second
100 mg/mg/1	Dr. Ramakant Nayak Principal
	M M's. N.G. Halgekar Institute of Dental Sciences

M.M's. N.G. Halgekar Institute of Dental Sciences & Research Centre, Belagavi-590010.

The research and alkal commettee meeting was anducted
at 10:00 on the confirme room in the college
office total 6 members attended the meeting. The
followy points were discussed,
@ Short shidy synopies submitted by Dr. Shakti and
@ Short study synopis submittel by Dr. Shakt was approved for athird clearens.
@ All SEC committee manbers should register for Culfied
online Trainy program on besearch ethis source committee
in 2nd GCP and werest regulations on 12.11-2020
onlive Training program on fescarch ethis, souried committee in Ind GCP and west regulations on 12.11-2020 anderled by Dayanaka Sayae College of dutal commit-
3) Sympsis presentation for of Durelation press will be
3) Sympas presentation for of Duralation These will be organized in the month of January.
Attended by -
Dr. Rangameth N. 10/11/40
Dr Hallikernath Frt 10/11/20
Dr. femilia A.
1/26
D1- Pari 5,
Dr. Howshed H. Ing
Dr. Proven M Mu 11,20
In Mo.
Dr. prace. E Perocey for
Dr. Ramakant Nayak Principal
M M's. N.G. Halgekar Institute of Dental Sciences & Research Centre, Belagavi-590010.

e Ethical committee	meeting will be held on
12 20w at 10.00 am	at the conference yours
the college office. All	the staff members are requested
make it comment t	o attend the same. HAAC criteria
.3.1 which is regarding	IEC has to be discussed.
Members:	Signature
Rangarath N.	02/ENIN
	N N
Renulea A.	(Among)
Praven Kumar M.	PAN OF THE
Rain S.	Jus.
Rajendra H.	But
Chandrashe Khae Y.	eyw.
- 177	60/
Prachi s.	fradi
Babe Metged	
7	1300
Chetuna B.	Cardio.
	Jus
	D. Harshade H.
497(13) 1933(13) 193	Member Sciretary
	the Land
	Dr. Ramakant Nayak Principal M.M's. N.G. Halgekar Institute of Dental Science & Research Centre, Belagavi-590010.

had committee neely was
at the conference man in the
6 membere attended the
pointe une discusse d.
t feb 2021.
1 teb 2021.
submission of reased synopsis
submission of reased ignophie
- OPTING m.
July 3/12/20
Jun 3/121
Ω_{∞}
मिनां र
D .
3/12/2020
m 30 9/11/2020
22°
BI
lev .
Dr. Ramakant Nayak Principal
M.M's. N.G. Halgekar Institute of Dental Sciences & Research Centre, Belagavi-590010.


The institutional Ethical committee meeting will be
held on 18.1.2021 at 9.00 am at conference room in
the college office. All the committee members are
requested to make it convinient to attend the same. Sympsis
of short study submitted by 16 student has to be discussed.
P. G. duscrtation synopsis prescutation has to be planned.
Looks A. Stormer
Members -
Dr. Rayanath N. 25
e/
Dr. Renuka A.
Dr. Rajandra H. Bit
Dr. Chandrashekhar Y. Bollagne.
Dr. Prachi S Juani
Dr. Baba Metgud
Dr. Chetana Bogas Composition 13/1/21
6
Dr Vikran Pai "Last. 121, 121.
Dr. Kolvekar.
Ing.
a. Harshade 4.
Member Scaretary
Lord Mayak
Dr. Ramakant Nayak Principal Principal
M.M's. N.G. Halgekar Institute of Dental Sciences M.M's. N.G. Halgekar Institute of Dental Sciences 8. Research Centre, Belagavi-590010.
8. Research Centre, Belagavi-5900 to.

The IEC meeting was held on 18.1.204 at the
continue norm in the college office. Total 7 members
The JEC meetry was held on 18.1.204 at the conterne norm in the college efficie. Total 7 members attended the neetry. The following points were discussed.
1. Pricipal had Englested that PGs should not be
given MOC bil bley cubmit the monuteriet copy of Discolation work. This doce not come fall under
the permin of 2EC. The above practice should
he permin of IEC. The above practice should be mandetal by Individual departments on the administrative affire
00
2. De Krifter Kadem to submit the count for for
3. Renuncation for the other party party members to
a. iveliare address to be given by Dr. Hendhole
5- De benuke will give note of thanks.
c. Coerentrars Engestions will be noted by De fracti
7. Suggestion was made by all finishe to include a pharmaint in the comillies, ale Mallech's name was suggested and appeared by the committee members.
a promeint in the comillies, ole Mallech's name was
suggester and opposed by the committee members.
e. Refrennete - les bourints le le accompulley Q Chetane.
Attended by
all leads A
all Miles P. White
and stallikament and
Dr. Ramstant Navel
Dr. Ramakant Nayak
M.M's. N.G. Halgekar Institute of Dental Sciences & Research Centre, Belagavi-590010.

The IEC meeting will be	held on 29.1.2021 at n in college office. All the
quoan at conference room	n in college office. All the
committee members are reque	aced to make it can
attend the same Sympsis a	of 1.9 dissertation have to be
discussed	
Members:	
Members: Dr. Rangareth H.	Leave
•	· / /
Dr. Remelia A.	Ar 8.
	Lecture,
Dr Rojendra H. L X	No.
0/	4> (an Leave on 29/1/2021)
1 090	
Dr. Chetana B. CMDet	
to the fe there !	son leave on solila)
De Vileran P. John !	
Dr Kolinkas	
Dr Kower	
hi	, by
Dr. Ramakant Naya Principal	or Hushed H.
Principal M.M's. N.G. Halgekar Institute of De Research Centre, Belagavi	i-590010.
& Messalett and	
1	
1000	
the state of the s	

The state of the s	
PG. Dissortation synopsis perio	Polis for you 2020-21
the let year mos statute a brostlodother and knowledgy per then Directation.	
as well as others use toward of the	
The Plas were asked to into	The state of the s
Attended by:	
O Da Anjoura Bagemadi	Que 3/2/21
Dr Roopal: Sunkeshwani -	Mrunt.
Mr Vijay More	
). De Rongenan Nayak.	- Slywy
Dr Ramakant Nayat	for
Dr Pomben Amening	Paris P
8) Der Harshada Halgekore	Jus Lev
DR RB Halli Konmoth	Dr. Ramakant Nayak Principal M.M's. N.G. Halgekar Institute of Dental Scie & Research Centre, Belagavi-590010.

Ph. Dissectation Synopsis	presentation for year 2020-21
The 1st year MOS st Conservature dudsty, Orth presented the symphy or	redute of department of a danters and Tedosfortes
The proposals were disco	
- The 16s were asked	or hefer 12th Feb 2021
Attended by-	
1. Dr Anjana Bayewadi	
2. Dr. Ropali Sonkeshwasi	
3. Mr. Umest Tardal	Amort
4. Dr. Rongrath Hanjak	2.4/2/01
5. Dr. Renuka Ammanagi	Bung
C. Dr. Chetona Boyan	Cm 23
7. D. Hallikee math	BU 412/21
8. D. Healtern Heustide H.	gues 1
9 De Madhu Rijan	Dr. Ramakant Nayak
10. gr. Pallari 9	Principal M M's. N.G. Halgekar Institute of Denta & Research Centre, Belagavi-590



IEC meeting was held on 9.2 2011 at the wifeme
rum in college office total 6 members attended the
med in Follow to I will
The meeting was held on 9.2 2021 at the contense room in college office total 6 members attended the meeting Following points were downed.
- Period compair of 1-6 dissetation were downed.
- Short study submitted by D. Knobka Kadom was dinumed and approved.
- Sheet study submitted by Dr. Haish and D. sowing a was approved.
- Dr. Rongant Majak Suggested that Bo the curstiments of sec members he changed and as follows. The following members are not the part of DEC
of sec members he closed and as follows
The following members are not the part of DEC
as of today -
1. D. Cladratikha Yavaral 4. Dr. Ray shorhette
1. Dr. Chandrashekhu Yavayal 4. Dr. Raii shirhetti 2. Dr. Prancenkumae Mandreli
2 0 A.h. Alfand
3. Dr. Bake Alged
- Two new members are appointed as members
of IEC. from !
1. Dr. Vikeam Pai
2. Dr. Kolvelar.
- This is done in wegulfather with Principal.
- Publishers ethis downt was approved.
Attraced by-
1. Dr. Rengarel Nayak
2. Dr. Regndes Hallikeemith Eit
3. Dr. Beruka A.
4. Dr. Practi katte hu Quacui
Dr. Ramakant Nayak Principal M.M's. N.G. Halgekar Institute of Dental Sciences & Research Centre, Belagavi-590010.

5. Dr. Chebens Bogar	International Contraction of the
6. Dr. Houskede slalge Kas	, the
TEC M. I'	4/10/2021
IEC Meeting	
of An elbrical comittee meeting dept. of Periodontology with the Comittee and the Pollon	h lha
(UG/PG), the synopsis is curry member of comiltee	be marted to each &
Is also suggested by	Dr. Kottrashetty to taket
nstitutional policy for uga Annual for the purpose	he meeting to form an students with Or.
of college ethical comittee of lose taken from Dr. Di	ake a note on renewal and any necessary advise
comittee members was collected	u the college elbical
The state of the s	cd.
Attended by:	Dr. Ramakant Nayak

0. Chandiashchar Dr. Hallehermath . Dr. Kottocabelly . Di Chelana 6 Dr. Remba Amaraga 24/11/2021 IIC Meeting is In the meeting, the renewal process of the institutional ethical comiltee was discussed. There were vanous inputs from the comittee members Dr. Vijay taxmi suggested that the renewal process for the new ethical comittee could take some time, so. bence and as they institute is going for MAAC accrediation. The chairman & the member secretary of the registered comittee to continue. Or Vihram who was the p member secretary during the registration a instructional ethical comittee said that, 2 years - of his 10 year is over. Il was also eaid by Dr. Vikiam that ethical comilter is not registered for clinical tricle Dr. Hallikerimoth suggested to continue the same - comittee with Dr Anjana Bagecoadi as chase person 4 Dr. Vikiam as member secretary. 03 The was also discussed that all the mail to be sent to 1 mode ethreal comitée @ gmail.com Any correspondence of through the ethical comittee will be through mail.

Principal

M.M's. N.G. Halgekar Institute of Dental Sciences

& Research Centre, Belagavi-590010.

The second secon	
04 Il was also discus	sed about the new ICMR
gurdelina All the me	imbers of the comittee were
asked to go through	the ICMR quideling and
also to find out the	etd CDESCO guidelines
05. Elbical clearance to	be given to all the short
study sub milled after	doing occessorie change i
Or. Anukumar, Or. Hanp	irya & Oi. Ekta.
of hrs study.	ed to submitted the synopsis
of All the members also	discussed about the plages
of Dr. Anuradha suggested	checker x' as a software
prugansm	
09 Turnita' was suggested	by Dr. Vijaylaxmi
10. Os Hallikiremoth sugger	led Viper'
11. Or Renuka said that	there soft wares needs to be
subscribed & renewed	yearly
Altended by:	
1 Dr. Sandecp	(n./1/24
2. Dr. Chandrashekor.	CHANNY 24/11/21.
3. Or Vijay laxmi	Definally V
4. Or Renuka	Danie 2 HINRI
c O- U-W-L - W	
	Buo
Dr. Halliktremalh	Quegler 24/11/21.
	Anador 24/11/27.

Dr. Ramakint Nayak Principal M.M's. N.G. Halgekar Institute of Dental Sciences & Research Centre, Belagavi-590010.

The institutional and
the institutional Educal committee meeting will be
at 900 am at contestente room in
the winites manked are
Time it convinced to attend the same sympsis
districted by 11 strict had to be discussed.
propers procedution has to be planned.
Dr. Rangarath H.
Dr. Carronall as
James W.
Dr. Regular A. 11 h. Com
Dr. Rayendra H. BJ
Dr. Rayendra H. Est Dr. Chandrashekhan Y. Ellyme.
D. Pradi 5.1 - Jucan 13/1/2021
13/1/2001
Dr. Babe Metged
1.47
Dr. Chetona Bogas 1 mbs. 13/1/21
Dr. Mikrom Pai
84 2 . A \$10 /4
Dr. Kolvekor. 91
1) I see I is suggested to
a. Harshade 4.
Membre Scenctory
I'm the total to the time to t
the list of 11/11 the
Dr. Ramakant Nayak
N. O. Haldekar Institute of Days to
& Research Centre, Belagavi-590010.


The IEC meetry was held on 18-1204 at the contenue noon in the college office. Total 7 members alterded the needy. The following points were discussed -1. Pricipal had suggested that PGS should not be gives MOC till they submit the monuscrapt copy of Discolution work. This does not come fall under be permis of DEC. The above practice should be mandell by sordindul departments as the administrative office. 2. De Krubia Kadom to submil the consultyoutor her short study, 3. Remember for the othe publishing members to be avergul a. welcome address to be given by a stended. 5. De lenuka will give note of thanks. Corrections Inguistions will be noted by De fract; 7. Suggister was made by al fruke to include a pharmacist in the comillies, ale Mallest's name was suggested and appeared by the committee members . Refressent - Cen pleasant to be arranged by D. Cholane. Attended byof alter inter De layanth N. HAMINA, Jam 8 18/1/21 Da. Brahi - Precis De Harchede and stall being the

> Dr. Ralmakant Nayak Principal M.M's. N.G. Holgekar Institute of Dental Sciences & Research Centre, Belagavi-590010.

low

he sec mution	. Al la 111
voom at confere	will be held on 29.1.2021 at nee room in college office. All the
miltre members a	nee room in college other. All the
thend the same	ce requested to make it convinted to
discussed.	Sympsis of 1-G diskybation have to be
Members: Dr. Rangarell W.	
Dr. Rangarell M.	leas.
	lean
D. Remilia A.	0 8
	W. T.
Dr. Rojendra H.	c but lecture.
Dr. Prachi K.	france > (an Leave on 29/1/2021)
Dr. Chetana B.	CM 39
	ula la maria a
D. Vilerem P.	liter (sor here on sality)
n VI lan	
Dr. Kolvekaa	
•	Dy.
	or stenshide st.
	in
	Dr. Ramakant Nayal
	M.M's, N.G. Halgekar Institute of Der
	& Research Centre, Belagavi-

91	3.2.2021
PG. Dissertation synapsis per	21.
0	for your 2020-21.
hostlodative and secondartalogy of	
worthodolin and feciodentalogue.	of cepatrick of
their Directation.	earner the synquis of
as well as othered issue. The admind were conveyed to the	A. A
as well as allered the	It length for the sentific
adujul mee	- Engether and changes
to the	P. to schudente.
apy le the DEC on se befo	
copy le the DE	mit the rained synapsise
I an or bufo	e 8th Feb 2021,
A	
Attended by:	
Dr Apjana Bagewadi	(D) a
	1 101
Dr Roopal: Sunkeshwari -	A. 3/2/21
	1
Mr Vmesh. Yourdal.	Mount
	U C
Mr Vijay More	
9	
). Dr Renganaon Nayak.	- slum
and the same of th	Siding
Dr Ramakast Nayat.	
Dr Jeanavait Mayat.	m
	0 13
Dr Penylea Amononagi	Pany
	V
Dr Harshada Kalgekon	303
7	
DR R B Halli Korimoth	Dr. Ramakant Navak
DR R B Halli V	D. H. Harrison
on the boundary	M.M's. N.G. Halgekar Institute of Dental Scien <u>& Research Centre, Belagavi 590</u> 010.
	6 Kesearch Centre, Belagavi-59001Q.



P.4. Dissertation Synopsis presentation for year 2020-21	
To the same of the	
The 1st year M.D.S students of de fruit of	mar
- The 1st year M.D.S students of department of Conscevation deals by Orthodorties and Tedestortes presented the symphys of their dissectation.	
presented the sumpoline	
of their dissentation.	
- The march	
scientify were discussed at high for the	
Class I will as othical Issues. The suggestions and	
conges advised were conveyed to the P. & students.	
The proposals were discussed at high for the scientific as well as adhiral Issues. The suggestions and Changes advised were conveyed to the P. & students.	100°
- The P-65 were asked to submit the revised sympsis copy to the JEC on or hefre eth Feb 2021	
copy to the DEC on or help of El and	
The FEE WILL	
Attended by-	
a.	
1 Dr. Angana Bayen adi	
2. Dr Ropali Sankeshwazi	
$\hat{\cap}$	- 1-
3. Mr. Umah Yardal	
	1
4 0 0 11	
It Kongrath Hayak 24/24/24	
5. Dr. Renuka Ammaraj. Amm	
V	
6. Dr. Chetana Bugas	-
7. A Hallikeimath BW-	
7/2/2/	
8 D. Jedlikeen Hershile & Jus	-
9 De Madhu Rijan Mp	man .
Dr. Ramakant Nayak	
10. Dr. Pallari G P. M.M's. N.G. Halgekar Institute of Dental Science	
& Research Centre, Belagavi-590010.	-
	-

(ii) Dr. Prochi. Katti - Guachi/
12 De Verendon Uppm A
13 Dr Hemart. Vageneli: &
14 De Cluban Patil 9/2/4
15 De Asin Jamasane
16 Dr. Ramakat Hayak Pm
17 a lap rede B
18 De Siddlart Revarkar 85
19. Or Bhatti Halakaravar &.
20. Dr. Trerom lan telai
21. Dr. Chandrasteker Yavayal Clavajal
りた Ramakant Nayak
M.M's. N.G. Halgekar Institute of Dental Science & Research Centre, Belagavi-590010.

Arc
TEC meeting was teld on 7.2.2011 at the conferme norm or college office Total 6 members attended the meeting. Following points were downed.
num in college office total 6 members attended the
meeting tollawing points were downed.
- Sevind appopul of 1-6 dissertation were discussed.
- Sheet shit. I all
discured and
- Sheet study subnitted by D. Knobles Kadom was discussed and approved,
- Sheet study , P. H. I. I. S. L. I. I.
- Sheet study submitted by Dr. Hawish and Q. sowny a
- Dr. Romant March Gooded let a 4 . 111+
of the members by the I all
The following much is all and as following
- Dr. Rongaret Mayak Suggested that Br. the custiments of ZEC members he clarged and as follows. The following members are not the part of ZEC as pf today -
1. Dr. Chandrashekhu Yavayal G. Dr. Rai Shirhetti.
1. Dr. Chandrashekhu Yavayal 4. Dr. Rais Shirhette. 2. Dr. Prancenkumae Mandrali
3. Dr. Baby paetgrd
- Two new members are appointed as members
of JEC. from !
1. Dr. Vikeam Pai
2. Dr. Kolvekay.
- This is done in wesultation with Principal.
- Publisher ethis downt was approved.
Attack by-
1. Dr. Rengarell Nayak
1 3
2. Dr. Ragnola Hallikeemith Est
3. Dr. Renuka A. Dang
4. Dr. Practi katti MV Quacui
Dr. Ramakant Nayak
M.M's. N.G. Halgekar Institute of Dental Sciences & Research Centre, Belanavi-590010

	4
5. Dr. Chebens Bogar	
6. Dr. Houshede stalgekar. The	
4 10 2021	
TEC Meeting	
of An ethical comillee meeting was conducted dept. of Periodontology with the new members the comillee and the Pollowing points were d	15 01
(UG/PG), the synopsis will be marked to the covery member of comiltee Any changes in synopsis should be done via mail.	each 4
→ Il is also suggested by Dr. Kottrashetty ! List of external members from Dr. Renuka.	o take the
The is also suggested in the meeting to for institutional policy for ug students with Or Anniadha for the purpose of research.	irm an
→ Il is also suggested to take a note on	renewal
of college elbical comittee and any necessari	y advise
of college elbical comittee and any necessari	y davise

2 Or Chandrashchar	alms
, Dr. Hallikerimath	EN BUY
4 Dr. Kollocubelly	(70)
5. D. Chelana	carlog
6 Da Remba Ammarage	0 4
-	(James
IEC Meeting	24/11/2021
of Io the	
of In the meeting the	renewal process of the
C. C. COMI	Hee I D
The state of the	
	0001112
THE THEFT	is done
	0 % the
TEGISTETED CON	office to cooking on the
THE THE COLOR	Secretare August II
The state of the s	cemittee enid that a
year is our	r. I was also easily
That that ethical	comiltee is not registered
for clinical trate.	
0) Dr. Hallikerimath 84	ggated to continue the same
comiltee with Dr. Anjac	a Bagasadi as chass person
& Dr. Vikram as mem	ber secretary
03. The was also discus	sed that all the mails
to be sent to 1 mmd	celbucal comiller (2)
Any correspondence of thro	with the W
will be through mail.	ine ethical comittee
or though man.	
	flow.
- Aller Aller	Dr. Ramakant Nayak
	M.M's. N.G. Halgekar Institute of Dental Sciences
	& research Centre, Belagavi-590010.

As containing excellent controls and the second controls and the second controls and the second controls and the second control controls and the second controls and the second control controls and the second control controls and the second control control controls and the second control control control controls and the second control contro	I IL DES IGME
04. Il con also discussed	about the new torse
delines All the member	SIZ OF THE CONTRACT
acked to as through the	Terik garatina
also to find out the	d CDESCO quidelines
	and the same of th
05. [thical clearance to	be given to all the short
study submilted after	doing necessary changes by
Or Anukumar, Or Hanpiry	a & Or. Ekla.
06 Dr. Yavgal sou asked	to submitted the synapsis
of his study	11 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
and the second second	att mater from meet
07. All the members also	discussed about the plaganson
softime for the metitate	the state of the s
34	William and and the same
08 Dr. Anuradha suggerted	checker X as a software
for plagarism	
09 Turnita vou suggested 1	Dr. Vijaylaxmi
10. Os Hallikiremoth suggeste	d Viper
11. Or Renuka said that	thuc soft war needs to be
	carly.
, , , , , , , , , , , , , , , , , , , ,	
Altended by:	
1. Dr. Sanderp.	() n/u/2
2. Dr. Chandrashekor	BY AVAY 24/11/21.
	DEF 24/1/21
3. Dr. Vijay laxmi	Do Buluki
	Buller
5. Or Hallskiremalh	Charles - wish
6. Dr. Anuradha	Most Julius
7. Or. Chetna	Wai 13
S. Dr. Vikram.	Dr. Ramakant Nayak
 Discrept State of the Control of the C	Delasitat

M.M's. N.G. Halgekar Institute of Dental Sciences & Research Centre, Belagavi-590010.

IEC Meching	
recenng	31/01/2022
Agenda	
discussion of short study students. All studia were issue of ethreal clearance change.	synopsis by the PG
in the new batch of February beld in August.	laxu, the supposes prescalation
requirement of re-regist	that, there was no ration of the etheral
14. Or Vijaylaxmi suggeste	d 2 alaganson software
along with quatation	
ask for the following:	
- Whether there were	
uploads with the s	oltware
→ Single or multiple → Limited or unlimited	
	P .
15. Dr. Anuradha suggerted.	a plagansm software
Dr. Renuka suggested	one plagansm software
	the entire Maratha Mandal
-, group	- 5 Havak
	Dr. Ramakant Nayak Principal
	M.M's. N.G. Halgekar Institute of Dental Sciences & Research Centre, Belagavi-590010.

Altended by :	(2) 31/12
1 Or Sandeep	ONLEAVE
2. Dr. Chandrachekar	Dets 2
3. Dr. Vijay laxmi	A M
4 Dr. Renuka	your o
5. Or Hallikeremath	No. of the second secon
6 Or Anuradha	and
7. Or Cheloa	Mat
8. Or. Vikram	
and the second s	lh.
	Dr. Ramakant Nayak
	Principal Principal Principal
	M M's. N.G. Halgekar Institute of Dental Science & Research Centre, Belagavi-590010.
100	ALC: ALC: ALC: ALC: ALC: ALC: ALC: ALC:
	The state of the s
•	
The second secon	
	The second secon

Dr. Ramakant Nayak
Principal
M.M's. N.G. Halgekar Institute of Dental Sciences
& Research Centre, Belagavi-590010.

1/6/2022= IEC Meeting Agenda -1/6/22 Dr. Ramakant Nayak Principal M M's. N.G. Halgekar Institute of Dental Sciences & Research Centre, Belagavi-590010.

SYNOPSIS PRESENTATION 4/6/2022 TEC Sympsis Presentation Agenda er in the IEC 1/6/2022 college andio formion for the Spropsis present for the - Total of 15 smapsis were presente scentinged for corre - A total of 8 minutes were alloted from each presenter [P5 stude Corre - All the members present 4 EP.T.O Dr. Ramakant Nayak Principal-M.M's. N.G. Halgekar Institute of Dental Sciences. & Research Centre, Belagavi-590010.

Maratha Mandal's NGH Institute of Dental Sciences & Research Centre, Belagavi.

DATE: 04/06/2022

INSTITUTIONAL ETHICAL COMMITTEE - P.G SYNOPSIS PRESENTATION 2022

NAME	DESIGNATION	SIGN
DR. ANJANA BAGEWADI	CHAIRMAN	A 6 22
DR. SANDEEP KATTI	MEMBER SECRETARY	15 4/6/n
DR. RENUKA AMMANAGI	MEMBER	on Leave
DR. HALIKERIMATH	MEMBER	B 04/06/22
DR. VIJAYLAKSHMI K	MEMBER	Qm/2 2/6/22
DR.CHANDRASHEKAR. Y	MEMBER	Ol Sre 4/6/22
DR. CHETANA. B	MEMBER	N10 16/22
DR.ANURADHA. B	BIOSTATISTICIAN	Jan 4/6/22
ADV. UMESH YARADAL	LAWYER	WILL 11/22
MR. VIJAY MORE	SOCIAL WORKER	Maran 16/22
MR. Nikhil. Kadrol	BOX LAY MEN	Alabrel In 4/6/22

Participante attended the Precentation:

9 no name

3 Paretti kungel

4) De Madhe Pugar

3) De Shutal Kulouruel

4) Dr. Reshma Faras

5) Dr. Pallari G

6 Dr Verendre Uppri

7 Dr. Rushule Theusa

8. Dr. Deepa. K

9 Dr. Cheepa. K

Dr. Ramakant Nayak

M.M.s. N.G. Halgekar Institute of Dental Sciences & Research Centre, Belagavi-590010.

12) Dr Hernant. T. V

10. Do Syprit Pawar

13) Des Viplain Charen-Parl	Oplan
13) Dr. Shruti Virupaxi 16) Dr. Pooja Mastannanavan	Roy.
15) Dr. Shruti Virupaxi	g-uv ,
16) Dr. Pooja Mastannanavag	7 uc 20
17) Dr. Widdhartt. Ecranta.	88
18) Dr. Vikram Pan.	vola:
19) Do Wilay Meil	(A)
20) DR RB Hallikorinalh	FI
br-Aarek Nayou	Um.
22) Dr. Proti Hraj	FIGR 4/6/2022
	4/61
22) Dr. Ajaykumas. Nagak	a
	—
	Jan Jan
	Dr. Rama ant Nayak
	Principal Principal M.M's. N.G. Halgekar Institute of Dental Sciences 8 Research Centre, Belagavi-590010.
	& Kesearch Centre, Sons

INSTITUTIONAL ETHICAL COMMITTEE POLICY DOCUMENT



Maratha Mandal's NGH Institute of Dental Sciences & Research Centre RS. No. 47A/2, Bauxite Road,

Belgaum- 590010 Karnataka State.

Contact phone: 91-831- 2477682

Email: mmnhgids@gmail.com

Dr. Rama kant Nayak
Principal
M.M's. N.G. Halgekar institute of Dental Sciences
& Research Centre, Belagavi-590010.

Contents

I. Short Description of SOP
II. Adoption of SOPIII. Objectives of SOP
IV. Authority for constituting the MMNGHIDS IEC
V. Role and Responsibilities of MMNGHIDS IEC
VI. Composition of MMNGHIDS-IEC
VII. Requirements for IEC Membership
VIII. Quorum requirements
IX. Conduct of MMNGHIDS IEC meetings
X. Independent consultants
XI. Application procedures
XII. Documentation
XIII. Review procedures
1. Exemption from review
2. Expedited Review
3. Full Review
XIV. Aspects considered during review of research proposal
XV. Decision-making
XVI. Communicating the decision
XVII. Following up procedures for approved proposals by PI / Sponsor
XVIII. Responsibilities of Sponsor/Investigator
XIX. Record keeping and archiving at the office of MMNGHIDS IEC
XX. Updating MMNGHIDS IEC members
XXI. Terms of reference
XXII. Administration and Management
XXIII. Special Considerations / Protection of Vulnerable Population
Annexure 2B [Format for submission]
Annexure 3A [Ongoing Approved Research Review Submission Form]
Annexure 3B [Format for submission of revised/additional documents]
Annexure 3C [Six monthly progress of Project]
Annexure 4 [Patient Information Sheet English]
Annexure 5 [Patient Information Consent Form English]
Annexure 6 [Data Elements for reporting serious adverse events]
Details of MMNGHIDS IEC members
Details of Supporting Staff

I. Short Description of SOP

The following are called as "Standard Operating Procedures for the Institutional ethics committee (IEC) of Maratha Mandal's NGH Institute of Dental Sciences & Research Centre, Belgaum".

II. Adoption of SOP

Maratha Mandal's NGH Institute of Dental Sciences & Research Centre, Belgaum herein after referred to as "MMNGHIDS" has adopted these written Standard Operating Procedures (SOP) to ensure the protection of the rights and welfare of human participants in biomedical, experimental and behavioral research conducted at MMNGHIDS.

III. Objectives of SOP

The objective of this Standard Operating Procedures of the Institutional ethics committee (IEC) of Maratha Mandal's NGH Institute of Dental Sciences & Research Centre, Belgaum is to maintain effective functioning of the MMNGHIDS-IEC and to ensure quality and technical excellence and consistent ethical review of all the submitted health and biomedical research proposals and ongoing approved research studies involving human participants in accordance with the ICMR ethical guidelines for biomedical research on human subjects.

IV. Authority for constituting the MMNGHIDS IEC

The Principal in consultation with the Chairperson, MMNGHIDS will appoint the Committee Chairperson and all the committee members based on their competence, experience and integrity by sending an official request letter Members will confirm their acceptance to the Principal by providing all the required information for membership. The Committee Chairperson will furnish any information or report to the Principal, MMNGHIDS when required.

V. Role and Responsibilities of MMNGHIDS IEC

The MMNGHIDS-IEC will review all types of research proposals involving human participants with a view to safeguard the dignity, rights, safety and well being of all actual and potential research participants before approving the research proposals. The goals of research, however important, should never be permitted to override the health and well being of the human participants.

The MMNGHIDS-IEC will ascertain whether all the cardinal principles of research ethics viz., *Autonomy, Beneficence, Non – maleficence, Respect for Free and Informed Consent, Respect for Human Dignity, Respect for Vulnerable Persons , Respect for Privacy and Confidentiality and Justice* are taken care of in planning, conducting and reporting of the proposed research. For this purpose, it will look into the aspects of *protocol review, selection of participants, voluntary participation of potential participants, informed consent process, risk benefit ratio, distribution of burden and benefit, maintenance of privacy and confidentiality and provisions for appropriate compensations.* It will review the proposals before the commencement of the study as well as review periodically until the completion of the study through appropriate well documented procedures. Such a review may be based on the periodic study progress reports furnished by the investigators and/or monitoring and internal audit reports furnished by the Sponsor and/or by visiting the study sites.

The mandate of the IEC shall be to review all research projects to be conducted at the Institution involving human beings directly or indirectly, irrespective of whether the research project is funded or non-funded, and if funded, then irrespective of the funding agency.

MMNGHIDS IEC will provide advice to the researchers on all aspects of the welfare and safety of the research participants after ensuring the scientific soundness of the proposed research.

In case MMNGHIDS IEC revokes its approval accorded to a trial protocol, it will record the reasons for doing so and immediately communicate such a decision to the Investigator as well as to the Licensing Authority.

In case of serious adverse event or death occurring to the clinical trial participant, the MMNGHIDS IEC shall forward it's report on the serious adverse event or death, after due analysis, along with its opinion on the financial compensation, if any, to be paid by the sponsor or his representative, whosoever had obtained permission from the Licensing Authority as defined under rule 21(b) for conducting the clinical trial, to the Chairman of the Expert committee constituted by the Licensing authority under Appendix XII (gazette notification 30th January 2013) with a copy of the report to the Licensing Authority within twenty one calendar days of the occurrence of the serious adverse event of death. In case of serious adverse event, other than death occurring to the clinical trial subject, the

MMNGHIDS IEC shall forward it's report on the serious adverse event after due analysis along with its opinion on the financial compensation, if any, to be paid by the sponsor of his representative, whosoever had obtained permission from the Licensing Authority for conducting the clinical trial, to the licensing authority within twenty one calendar days of the occurrence of the serious adverse event.

VI. Composition of MMNGHIDS-IEC

MMNGHIDS-IEC will be a multidisciplinary and multisectorial body in composition and independent. The number of members of the Review Board may range from 7 to 15. The chairperson of the IEC will be from outside the Institution to maintain the independence of the Committee. The Member Secretary will belong to the same Institution and will conduct the business of the Committee. Other members will be a mix of medical / non-medical, legal, scientific and non-scientific persons and may also include members of public to reflect the different points of view.

There will be representation of age and gender in the Committee to safeguard the interest and welfare of all sections of the society. Member should be aware of local, social and cultural norms, as this is an important social control mechanism. IEC may invite subject experts to take their views, whenever it is needed.

The MMNGHIDS-IEC will include

- 1. Chairperson from outside the institute
- 2. One or more persons from basic medical science area (One pharmacologist compulsorily, one female member compulsory)
- 3. One or more clinicians
- 4. One legal expert or retired judge
- 5. One social scientist/ representative of non-governmental voluntary organization/agency
- 6. One philosopher/ ethicist/ theologian
- 7. One lay person (non-medical background) from the community
- 8. Member Secretary from within the institute

A Sub-Board of the main IEC may review proposals submitted by undergraduate or post-graduate students or if necessary, an IEC may be separately constituted for the purpose, which will review proposals in the same manner as described above.

VII. Requirements for IEC Membership

1. All members will serve for a period of 2 years on renewable basis. New members will be Included in the IEC in such a way that there will be a mix of recently included

members and members with some years of experience.

- 2. During the term, Principal in consultation with the Chairperson can disqualify any member if, the contribution is not adequate and/or there is long period of non-availability.
- 3. A member can tender resignation of his office of membership from the IEC to the Principal through the Committee Chairperson after serving one month advance notice.
- 4. Principal can replace the member of IEC as and when required.
- 5. Each member is required to sign the declaration and confidentiality agreement regarding IEC activities
- 6. Conflict of interest should be declared by members of the MMNGHIDS-IEC prior to review meeting.

VIII. Quorum requirements

Minimum of 50% of committee strength and not less than 6 members are required to constitute the quorum for the meeting of which at least one member has to be from outside the institution, and one member will be a non-scientific member & one from opposite gender. All decisions will be taken in meetings and not by circulation of project proposals. Quorum will have 6 members with following representations:

- (a) Basic medical scientists (preferably one pharmacologist).
- (b) Clinician
- (c) Legal expert
- (d) Social scientist/ representative of non-governmental voluntary agency / philosopher / ethicist / theologian or a similar person
- (e) Lay person from the community.

IX. Conduct of MMNGHIDS IEC meetings

The Committee Chairperson will conduct all meetings of the MMNGHIDS IEC. In the absence of the Committee Chairperson an alternate Committee Chairperson will be elected from the members by the members present, who will conduct the meeting. The Member Secretary is responsible for organizing the meetings, maintaining the records and communicating with all concerned. He/She will prepare the minutes of the meetings and get it approved by the Committee Chairperson and circulate among the members.

XI. Independent consultants

The MMNGHIDS IEC may call upon subject experts as independent consultants who may provide special review of selected research protocols, if need be. These experts may be specialists in ethical or legal aspects, specific diseases or methodologies, or represent specific communities; patient groups or special interest groups e.g. cancer patients, HIV/AIDS positive persons or ethnic minorities. They will be required to give their specialized views but should not take part in the decision making process which will be made by the members of the MMNGHIDS IEC.

XII. Application procedures

- 1. All proposals should be submitted on any working day 2 weeks in advance of scheduled meeting in the prescribed application form, the details of which are given under "XII Documentation". The applicant may ask for copy of SOP from the IEC, if the same has not been circulated earlier or not available on the website.
- 2. All relevant documents should be enclosed with application form. (Documents will be available with Member Secretary, MMNGHIDS IEC and Institutional Website (www.mmdc.edu.in).
- 3. Required number of copies of the proposal along with the application and documents in prescribed Copy format duly signed by the Principal Investigator (PI) and Coinvestigators/ Collaborators / Research Scholars shall be guided to the Chairperson MMNGHIDS IEC, through member secretary. In his absence via any person nominated by Chairperson, receipt of the application will be acknowledged by the IEC office.
- 4.Every application will be allotted an IEC registration number to be used for all future correspondence and reference. The date of IEC meeting will be intimated to the PI to attend the meeting and to make a brief presentation of the proposal and to clarify the points raised by the members.
- 5. The decision of the committee on the proposal will be communicated in writing. If revision is to be made, the revised document in required number of copies should be submitted within a stipulated period of time as specified in the communication or before the next meeting.

All research proposals/clinical trials funded/sponsored by Pharmaceutical companies, Agencies, Multinationals etc. will be charged an administrative fee/ processing fee of 5%. Waiver of these fees is permissible for non-funded studies, departmental studies, and studies funded by organizations like ICMR, UGC, DST Government of India, State Science & Technology Department, UNICEF, WHO, USAID, Non Profitable Organizations etc.

XIII. Documentation

All Research proposals (6 copies along with 1 CD/DVD) shall be submitted along with the information and documents as specified.

XIV. Review procedures

- 1. The meeting of the IEC will be held on periodic intervals, i.e. 1st Monday of Jan, March, May, July, Sep, Nov, unless otherwise specified by the member secretary. Additional review meetings can also be held with short notice as and when required. Meetings will be planned in accordance with the need of the work load. Provision will be made to call an emergency meeting on the advice of the Chairperson.
- 2.The proposals will be sent to the IEC at least 2 weeks in advance of scheduled meeting.
- 3.The IEC's member-secretary or secretariat shall screen the proposals for their completeness and depending on the risk involved categorize them into three types, namely, exemption from review, expedited review and full review (as described below).
- 4.Decisions will be taken by consensus after discussion, and whenever needed voting will be done. Decision of committee chairperson will be final.
- 5. Researchers will be invited for clarifications if need be. The PI / Research Scholar will then present the proposal in person in the meeting. When the PI is not available due to unavoidable reasons the Co-PI will present the proposal.
- 6. Independent consultants/experts will be invited to offer their opinion on specific research proposals if needed.
- 7. The decisions will be minuted and Committee Chairperson's approval taken in writing.

1.Exemption from review

Proposals which present less than minimal risk fall under this category as may be seen in following situations:

- •Research on educational practices such as instructional strategies or effectiveness of or the comparison among instructional techniques, curricula, or classroom management methods. Exceptions:
- 1. When research on use of educational tests, survey or interview procedures, or observation of public behavior can identify the human participant directly or through identifiers, and the disclosure of information outside research could subject the participant to the risk of civil or criminal or financial liability or psychosocial harm.

- 2. When interviews involve direct approach or access to private papers.
- 3.Expedited Review

The proposals presenting no more than minimal risk to research participants may be subjected to expedited review. The Member- Secretary and the Committee Chairperson of the IEC or designated member of the Committee or Subcommittee of the IEC may do expedited review only if the protocols involve -

- 1. Minor deviations from originally approved research during the period of approval.
- 2.Revised proposal previously approved through full review by the IEC or continuing review of approved proposals where there is no additional risk or activity is limited to data analysis.
- 3.Research activities that involve only procedures listed in one or more of the following categories:
- •Clinical studies of drugs and medical devices only when -
- 1.Research is on already approved drugs except when studying drug interaction or conducting trial on vulnerable population or
- 2.Adverse Event (AE) or unexpected Adverse Drug Reaction (ADR) of minor nature is reported.
- 4.Research involving clinical materials (data, documents, records, or specimens) that have been collected for non-research (clinical) purposes.
- 5. When in emergency situations like serious outbreaks or disasters a full review of the research is not possible, prior written permission of IEC may be taken before use of the test intervention. Such research can only be approved for pilot study or preliminary work to study the safety and efficacy of the intervention and the same participants should not be included in the clinical trial that may be initiated later based on the findings of the pilot study.

a. Research on interventions in emergency situation

When proven prophylactic, diagnostic, and therapeutic methods do not exist or have been ineffective, physicians may use new intervention as investigational drug (IND) / devices / vaccine to provide emergency medical care to their patients in life threatening conditions. Research in such instance of medical care could be allowed in patients -

i.When consent of person/ patient/ responsible relative or custodian/ team of designated doctors for such an event is not possible. However, information about the intervention should Copy be given to the relative/ legal guardian when available later;

- ii. When the intervention has undergone testing for safety prior to its use in emergency situations and sponsor has obtained prior approval of DCGI;
- iii.Only if the local IEC reviews the protocol since institutional responsibility is of paramount importance in such instances.
- iv.If Data Safety Monitoring Board (DSMB) is constituted to review the data;
- b. Research on disaster management

A disaster is the sudden occurrence of a calamitous event at any time resulting in substantial material damage, affecting persons, society, community or state(s). It may be periodic, caused by both nature and humans and creates an imbalance between the capacity and resources of the society and the needs of the survivors or the people whose lives are threatened, over a given period of time. It may also be unethical sometimes not to do research in such circumstances. Disasters create vulnerable persons and groups in society, particularly so in disadvantaged communities, and therefore, the following points need to be considered when reviewing such research:

- i.Research planned to be conducted after a disaster should be essential culturally sensitive and specific in nature with possible application in future disaster situations.
- ii.Disaster-affected community participation before and during the research is essential and its representative or advocate must be identified.
- iii.Extra care must be taken to protect the privacy and confidentiality of participants and communities.
- iv. Protection must be ensured so that only minimal additional risk is imposed.
- v.The research undertaken should provide direct or indirect benefits to the participants, the disaster-affected community or future disaster- affected population and a priori agreement should be reached on this, whenever possible, between the community and the researcher.
- vi.All international collaborative research in the disaster-affected area should be done with a local partner on equal partnership basis.
- vii.Transfer of biological material, if any, should be as per Government rules taking care of intellectual property rights issues.
- 6. Expedited review may also be taken up for nationally relevant proposals requiring urgent review.

3. Full Review

All research presenting with *more than minimal risk*, proposals/ protocols which do not qualify for exempted or expedited review and projects that involve vulnerable population and special groups shall be subjected to full review by all the members.

While reviewing the proposals, the following situations may be carefully assessed against the existing facilities at the research site for risk/benefit analysis:

- a. Collection of blood samples by finger prick, heel prick, ear prick, or venipuncture:
 - i. From healthy adults and non-pregnant women who weigh normal for their age and not more than 500 ml blood is drawn in an 8 week period and frequency of collection is not more than 2 times per week;
 - ii. From other adults and children, where the age, weight, and health of the participants, the collection procedure, the amount of blood to be collected, and the frequency with which it will be collected has been considered and not more than 50 ml or 3 ml per kg, whichever is lesser is drawn in an 8 week period and not more than 2 times per week.
 - iii. From neonates depending on the hemodynamic, body weight of the baby and other purposes not more than 10% of blood is drawn within 48 72 hours. If more than this amount is to be drawn it becomes a risky condition requiring infusion/blood transfusion;
 - iv. Prospective collection of biological specimens for research purposes by noninvasive means. For instance:
 - 1. Skin appendages like hair and nail clippings in a non-disfiguring manner;
 - 2. Dental procedures deciduous teeth at time of exfoliation or if routine patient care indicates a need for extraction of permanent teeth; supra and sub-gingival dental plaque and calculus, provided the collection procedure is not more invasive than routine prophylactic scaling of the teeth;
 - **3.** Excreta and external secretions (including sweat);
 - 4. Uncannulated saliva collected either in an unstimulated fashion or stimulated by chewing gum or by applying a dilute citric solution to the tongue;
 - 5. Placenta removed at delivery;
 - 6. Amniotic fluid obtained at the time of rupture of the membrane prior to or during labor;

- 7. Mucosal and skin cells collected by buccal scraping or swab, skin swab, or mouth washings;
- 8. Sputum collected after saline mist nebulization and bronchial lavages.
- b. Collection of data through noninvasive procedures routinely employed in clinical practice.

 Where medical devices are employed, they must be cleared/ approved for marketing, for instance
 - i. physical sensors that are applied either to the surface of the body or at a distance and do not involve input of significant amounts of energy into the participant or an invasion of the participant's privacy;
 - ii. Weighing or testing sensory acuity;
 - iii. Magnetic resonance imaging;
 - iv. Electrocardiography, echocardiography; electroencephalography, thermography, detection of naturally occurring radioactivity, electroretinography, ultrasound, diagnostic infrared imaging, Doppler blood flow,
 - v. Moderate exercise, muscular strength testing, body composition assessment, and flexibility testing where appropriate given the age, weight, and health of the individual.
- c. Research involving clinical materials (data, documents, records, or specimens) that will be collected solely for non-research (clinical) purposes.
- d.Collection of data from voice, video, digital, or image recordings made for research purposes.
- e.Research on individual or group characteristics or behavior not limited to research on perception, cognition, motivation, identity, language, communication, cultural beliefs or practices, and social behavior or research employing survey, interview, oral history, focus group, program evaluation, human factors evaluation, or quality assurance methodologies.

XV. Aspects considered during review of research proposal

- 1. Scientific design and conduct of the study.
- 2. Approval by appropriate scientific review committees / Research committee, if any.
- 3. Examination of predictable risks/harms
- 4. Examination of potential benefits.
- 5. Procedure for selection of subjects including inclusion / exclusion, withdrawal criteria and other issues like advertisement details.
- 6. Management of research related injuries, adverse events.

- 7. Compensation provisions.
- 8. Justification for placebo in control arm, if any
- 9. Availability of products, benefits to subjects after the study is completed if applicable.
- 10. Patient information sheet, informed consent form in English and in local languages.
- 11. Protection of privacy and confidentiality.
- 12. Involvement of the community, wherever necessary
- 13. Plans for data analysis and reporting.
- 14. Adherence to all regulatory requirements and applicable guidelines.
- 15. Competence of investigators, research and supporting staff.
- **16**. Facilities and infrastructure of study sites.
- 17. Criteria for withdrawal of patients, suspension or premature termination of a study in MMNGHIDS.

XVI. Decision-making

- Members will discuss the various issues before arriving at a consensus decision. When consensus is not arrived at, the decision will be made by voting procedure.
- 2. A member should withdraw from the meeting during the decision procedure concerning an application where a conflict of interest arises and this should be indicated to the chairperson prior to the review of the application and recorded in the minutes.
- 3. Decision will be made only in meetings where quorum is complete.
- 4. Only the members can make the decisions. The expert consultants will only offer their opinions.
- 5. Decision may be to approve, reject or revise the proposals. Specific *suggestions for modifications and reasons for modifications and reasons for rejection* will be given.
- 6. In cases of conditional decisions, clear suggestions for revision and the procedure for having the application revised will be specified.
- 7. Modified proposals will be reviewed by an expedited review through identified members.
- 8. Procedures for appeal by the researchers will be clearly defined.

XVII. Communicating the decision

1. Decision of the meeting on the proposals will be communicated by the Member

Secretary/secretariat in writing to the PI / Research Scholar within two weeks after the meeting at which the decision was taken in the specified format. All the approvals will be valid for one year or for the duration of the project whichever is less. Investigator has to get his or her project re- approved after one year, where required.

2. The communication of the decision will include:

- a. Name and address of IEC.
- b. The date, place and time of decision.
- **c.** The name and designation of the applicant.
- d. Title of the research proposal reviewed.
- e. The clear identification of protocol no., version no., date, amendment no., date.
- f. Along with protocol, other documents reviewed- Clear description of these documents along with Version No. and Date.
- g. List of EC members who attended the meeting- clear description of their role, affiliation and gender.
- h. A clear statement of decision reached.
- i. Any advice by the IEC to the applicant including the schedule / plan of ongoing review by the MMNGHIDS IEC
- j. In case of conditional decision, any requirement by IEC, including suggestions for revision, and the procedure for having the application re-reviewed.
- k. In case of rejection of the proposal, reason(s) for the rejection will be clearly stated.
- I. Signature of the member secretary with date.

XVIII. Following up procedures for approved proposals by PI / Sponsor

- 1. IEC will review the progress of all the studies for which a positive decision has been reached from the time of decision till the termination of the research.
- 2. Progress of all the research proposals will be followed at a regular interval of at least once a year. But in special situations, IEC will conduct the follow up review at shorter intervals basing on the need, nature and events of research project.
- 3. Periodic status report of study should be submitted at prescribed intervals for review, along with information and documents as specified, based on the safety concerns and this prescribed interval should be specified in the Letter of Communication of Decision to the PI from the IEC.

- 4. Final report should be submitted at the end of study.
- 5. Following instances and events will require the follow-up review/ Renewed Approval:
 - a. Any protocol amendment likely to affect rights, safety or well-being of research subject of conduct of study.
 - b. Serious or unexpected ADR related to study or product, action taken by Investigator, Sponsor and Regulatory Authority.
 - c. Any event or information that may affect the benefit/risk ratio of the study.
- 6. Protocol deviation, if any, should be informed with adequate justifications.
- 7. Any new information related to the study should be communicated.
- 8. Premature termination of study shall be notified with reasons along with summary of the data obtained so far.
- 9. Change of investigators/sites must be informed to the office of IEC.
- 10.Monitoring: Oversight mechanism will be in place to monitor the approved studies. Actual site visits can be made especially in the event of reporting of adverse events or violations of human rights and appropriate action will be taken when required and communicated to the applicant indicating modification/suspension/termination/continuation of the project. In case the IEC desires so, reports of monitoring done by the sponsor and the recommendations of the DSMB may also be sought.

Applicant must inform the time of completion of study and must send the result summary to IEC. IEC must receive a copy of final summary of study completed from the applicant.

XIX. Responsibilities of Sponsor/Investigator

Responsibilities of Sponsor

- (i)The clinical trial Sponsor is responsible for implementing and maintaining quality assurance systems to ensure that the clinical trial is conducted and data generated, documented and reported in compliance with the protocol and Good Clinical Practice (GCP) Guidelines issued by the Central Drugs Standard Control Organization, Directorate General of Health Services, Government of India as well as with all applicable statutory provisions. Standard operating procedures should be documented to ensure compliance with GCP and applicable regulations.
- (ii)Sponsors are required to submit a status report on the clinical trial to the Licensing Authority at the prescribed periodicity.
- (iii)In case of studies prematurely discontinued for any reason including lack of commercial interest in pursuing the new drug application, a summary report should be

submitted within 3 months. The summary report should provide a brief description of the study, the number of patients exposed to the drug, dose and duration of exposure, details of adverse drug reactions, if any, and the reason for discontinuation of the study or non-pursuit of the new drug application;

(iv)Any report of serious adverse event of death occurring in clinical trial, after due analysis shall be forwarded by the sponsor to chairman of the ethics committee and chairman of the expert committee constituted by the licensing authority as defined under rule 21(b) under appendix XII of gazette notification dated 30th January 2013 with a copy of the report to the Licensing authority and the head of the Institution where the trial has been conducted within ten calendar days of occurrence of serious adverse event of death. The report of the serious adverse event other than death, after due analysis, shall be forwarded by the sponsor to the Licensing authority, Chairman of the Ethics Committee and the head of the Institution where the trial has been conducted within ten calendar days of occurrence of the serious adverse event.

In case of injury or death occurring to the clinical trial subject, the sponsor (whether a pharmaceutical company or an Institution) or his representative, whosoever had obtained permission from the Licensing Authority for conduct.

- (i) Of the clinical trial, shall make payment for medical management of the subject and also provide financial compensation for the clinical trial related injury or death in the manner as prescribed in Appendix XII of gazette notification dated 30th January 2013.
- (ii) The sponsor (whether a pharmaceutical company or an institution) or his representative, whosoever had obtained permission from the Licensing Authority for conduct of the clinical trial, shall submit details of compensation provided or paid for clinical trial related injury or death, to the Licensing Authority within thirty days of the receipt of the order of the Licensing Authority.

Responsibilities of the Investigator(s)

(i) The Investigator(s) shall be responsible for the conduct of the trial according to the protocol and the GCP Guidelines and also for compliance as per the undertaking given in Appendix VII of schedule Y. Standard operating procedures are required to be documented by the investigators for the tasks performed by them. During and following a subject's participation in a trial, the investigator should ensure that adequate medical care is provided to the participant for any adverse events. Investigator(s) shall report all serious and unexpected adverse events to the Licensing Authority defined under clause (B) of rule 21 (Schedule Y and Gazette notification

30th January 2013), the sponsor or his representative, whosoever had obtained permission from the licensing authority for conduct of the clinical trial, and the ethics committee that accorded approval to the study protocol, within twenty four hours of their occurrence. The report of the serious adverse event of death, after due analysis shall be forwarded by the investigator to Chairman of the ethics committee and Chairman of the Expert Committee constituted by the Licensing authority under Appendix XII with a copy of the report to the Licensing Authority and the head of the institution where the trial has been conducted within ten calendar days of occurrence of the serious adverse event of death. The report of the serious adverse event other than death, after due analysis shall be forwarded to the Licensing Authority, Chairman of the Ethics Committee and the Head of occurrence of the serious adverse event.

(ii) The investigator shall provide information to the clinical trial subject through informed consent process as provided in Appendix V of Schedule Y about the essential elements of the clinical trial and the subject's right to claim compensation in case of trial related injury or death. He shall also inform the subject or His/ Her nominee(s) of their rights to contact the sponsor or his representative whosoever had obtained permission from the Licensing Authority for conduct of the clinical trial for the purpose of making claims in the case of trial related injury or death.

XX. Record keeping and archiving at the office of MMNGHIDS IEC

- 1. All the documents and communications of IEC will be dated, filed and archived in a secure place.
- 2. Only the member secretary or persons, who are authorized by the Chairman of IEC will have the access to the various documents.
- 3. All the documents related to research proposals will be archived for a minimum period of 3 years in the Institute, following the completion /termination of the study.
- 4. No document (except agenda) will be retained by any IEC member.
- 5. At the end of each meeting, every member must return the CD/DVD containing all the research proposals and documents to IEC office staff. They will archive one copy in IEC office and other copies will be destroyed after one year.
- 6. Following documents will be filed and archived with proper label on the top of file for easy identification
 - a. Constitution and composition of MMNGHIDS IEC
 - b. Curriculum Vitae (CV) of all members of MMNGHIDS IEC with records of training in Human ethics if any.
 - c. Standard Operating Procedures of MMNGHIDS IEC.
 - d. Annual reports
 - e. A record of all income and expenses of the EC, including allowances and reimbursements made to the secretariat and EC members;
 - f. The published guidelines for submission established by the EC.
 - g. Copy of all study protocols with enclosed documents, progress reports, and SAEs.
 - h. Agendas and Minutes of all IEC meetings duly signed by the Chairperson / Member secretary.
 - i. Copy of all existing relevant national and international guidelines on ethics and laws along with amendments.
 - j. Copy of all correspondence with members, Principal Investigators and other regulatory bodies.
 - k. Record of all notification issued for premature termination of a study with a summary of the reasons:
 - Final report of the approved projects, including microfilms,
 CDs and Video recordings.

XXI. Updating MMNGHIDS IEC members

- 1. All relevant new guidelines should be brought to the attention of the members.
- 2. The IEC members should be encouraged to keep abreast of all national and international developments in ethics through orientation courses on related topics by its own members or regular training organized by constituted body/ bodies, so that they become aware of their role and responsibilities. For drug trial review it is preferable to train the IEC members in Good Clinical Practice. Any change in the regulatory requirements should be brought to their attention and they should be aware of local, social and cultural norms, as this is the most important social control mechanism. This is needed for maintaining quality in ethical review

XXII. Terms of reference

Terms of reference will be maintained in the office of MMNGHIDS IEC. This includes

- A. Membership Requirements
- B. Terms of Appointment with reference to the duration of the term,
- **C**. The policy for removal, replacement, resignation procedure,
- D. Frequency of meetings, and
- E. Payment of processing fee to the IEC for review, honorarium/ consultancy to the members/ invited experts *etc*.

The SOPs will be updated periodically based on the changing requirements. The term of appointment of members could be extended for another term and a defined term and a defined percentage of members could be changed on regular basis. Preferably, IECwould appoint persons or persons

The SOPs will be updated periodically based on the changing requirements. The term of appointment of members could be extended for another term and a defined percentage of members could be changed on regular basis. Preferably, IEC would appoint persons or persons with trained in bioethics conversant ethical guidelines and laws of the country. Substitute member may be nominated if been continuously missed by a member due to illness or other unforeseen circumstances.

XXIII. Administration and Management

A full time secretariat and space for keeping records is required for a well-functioning IEC. The members could be given a reasonable compensation for the time spared for reviewing the proposals. Reasonable fees can be charged to cover the expenses related to review and administrative processes for any third party (protocols submitted by researchers not employed by MMNGHIDS) submission as described in section XI Point No 6. There should be provision for allocating reasonable amount of funds for smooth functioning of the IEC.

XXIV. Special Considerations / Protection of Vulnerable Population

While all the above requirements are applicable to biomedical research as a whole irrespective of the specialty of research, there are certain specific concerns pertaining to specialized areas of research which require additional safe guards / protection and specific considerations for the IEC to take note of. Examples of such instances are research involving children, pregnant and lactating women, vulnerable participants and those with diminished autonomy besides issues pertaining to commercialization of research and international collaboration. The observations and suggestions of IEC will be given in writing in unambiguous terms in such instances. ICMR guidelines as applicable will be followed for protection of vulnerable population.

Maratha Mandal's NGH Institute of Dental Sciences & Research Centre, Belgaum Institutional Ethics committee

Initial Review Submission Form for Research Proposal

- 1. Title of the research proposal
- 2. Name of the Principal Investigator with qualification and designation
- 3. Name of the Co-Investigator(s) with qualifications and designation
- 4. Name of the Institute / Hospital / Field area where research will be conducted
- 5. Forwarding letter from the Head of the Department / Guide in case of thesis proposals.
- 6. Protocol of the proposed research: (includes and not limited to) clear research objectives, rationale for undertaking the investigations in human participants in the light of existing knowledge, inclusion and exclusion criteria for entry of participants, precise description of methodology of the proposed research, including sample size (with justification), type of study design (observational, experimental, pilot, randomized, blinded etc.), intended intervention, dosages of drugs, route of administration, duration of treatment and details of invasive procedures if any, plan to withdraw or withhold standard therapies in the course of research, plan for statistical analysis of the study, ethical issues in the study and plans to address these issues.
- 7. Proposal should be submitted with relevant enclosures like proforma, case report forms, questionnaires, follow-up cards, participant recruitment procedures and brochures, if any. Informed consent process, including patient information sheet and informed consent form in English and local language(s) are mandatory. Investigator's brochure for trial on drugs/ devices/ vaccines/ herbal remedies and statement of relevant regulatory clearances should be attached. Source of funding and financial requirements for the project has to be detailed.
- 8. For any drug / device trial, relevant pre-clinical animal data and clinical trial data from other centers within the country / other countries, if available.
- 9. Usefulness of the project / trial
- 10. Expected 'benefits' to volunteers / community. 'Benefits' to other categories if any
- 11. Explain all anticipated (Adverse events, injury, discomfort) of the project. 'risks' Efforts

taken to minimize the 'risks'. trials, proposed compensation and reimbursement of For incidental expenses and management of research related and unrelated injury/ illness during and after research period. Description of the arrangements for indemnity, if applicable in study-related injuries and description of the arrangements for insurance coverage for research participants, if applicable

- 12. Agreement to report all Serious Adverse Events (SAE) to MMNGHIDS -IEC.
- 13. Other financial issues including those related to insurance.
- 14. An account of storage and maintenance of all data collected during the trial.
- 15. For international collaborative study details about foreign collaborators and documents for review of Health Ministry's Screening Committee(HMSC) or appropriate Committees under other agencies/ authority like Drug Controller General of India (DCGI)
- 16. For exchange of biological material in international collaborative study a MoU/ Material Transfer Agreement between the collaborating partners.
- 17. Statement of conflicts of interest, if any.
- 18. Agreement to comply with the relevant national and applicable international guidelines, Good Clinical Practices (GCP) protocols for clinical trials.
- 19. All significant previous decisions (e.g., those leading to a negative decision or modified protocol) by other ECs or regulatory authorities for the proposed study (whether in the same location or elsewhere) and an indication of the modification(s) to the protocol made on that account. The reasons for negative decisions should be provided
- 20. A statement on, probable ethical issues and steps taken to tackle the same like justification for washout of standard drug, or the use of placebo control.
- 21. Curriculum vitae of all the investigators with relevant publications in last five years.
- 22. Plans for publication of results / positive or negative / while maintaining the privacy and confidentiality of the study participants.
- 23. Any other information relevant to the study.
- 24. Signature of the Principal Investigator with date.

Note: The above information and enclosures should be furnished wherever necessary depending upon the nature of study proposal

FORMAT FOR SUBMISSION OF PROJECTS INVOLVING RESEARCH IN HUMAN SUBJECTS FOR CLEARANCE BY ETHICS COMMITTEE OF MMNGHIDS, BELGAUM

Submit six (6) hard copies of the Research Proposal along with Covering letter, a CD/DVD of the proposal and a 'soft copy' along with the following information to the Member Secretary, Institution Ethics Committee at the IEC office, MMNGHIDS.

No research project shall be / can be started unless ethics clearance/approval is obtained. Please bear in mind that no retrospective / post facto ethical clearance can be provided to research projects which were neither submitted nor vetted by the Institution Ethics Committee.

All submissions should be made in the prescribed Format of the IEC with signatures of all the investigators. The submission must be accompanied with *Participant Informed Consent Form* (PICF) and *Participant Information Sheet* (PIS), both in English and Hindi/Concerned local Language, in a simple layman's language, in a narrative form, directed to Participant/LAR, covering all the points given, before it can be considered for placing before the IEC. Also ensure that all the pages are numbered.

Project Submission Time: Submissions will be received on all working days. Proposals received till 15th of preceding month will be processed in the coming Institution Ethics Committee meeting and those received after 15th will be processed in the next Institution Ethics Committee meeting. All meetings of Institution Ethics Committee will be held as far as possible on first Monday of Jan, March, May, July, September, and November. The

frequency will change depending upon the number of proposals and will be updated on the website: **www.mmdc.edu.in**.

While submitting replies to queries raised by the IEC, the candidates are advised to mention the IEC reference number/s and also attach a copy of the comments of the IEC Moreover if the approval is required in a particular format, the same may be submitted in a CD/DVD.

Amendment Submission: While submitting amendments in protocols a covering letter should be provided clearly stating the changes and a certificate by the PI that the changes made in the protocol will not hamper the safety of the subject in anyway.

Form to be filled by the Principal Investigator (PI) for submission to Institutional Ethics Committee (IEC), MMNGHIDS

(For attachment to each copy of the proposal)

Serial No of IEC
Management Office:

Proposa	al Title:			
	Name, Designation, Department & Qualifications	Address Tel & Fax Nos. Email ID	No of projects already with Investigator	Signature
PI				
Co-PI / Collaborators				
1.				
2.				
3.				
4.				
5.				
6.				

publications limited to previous 5 years).

Please attach detailed Curriculum Vitae of all Investigators (with subject specific

Tick appropriately

Sponsor Information :						
1. Indian a)	Government	Centra		State	Institutional	
2. Private						
3. Industry	National	Multin	national 🔲			
Contact Address of Sponso	or:					
Total Budget:						
Who will bear the cost of	investigation /	Patients		Project	Exempted	
implants drugs / contrasts	?	Other A	gencies			
1. Type of Study: Cro	ss Sectional Ca	ise Control C	ohort	Clinical Tria	Review	
Sponsor Information :						
1. Indian a) Governme	ent Gove	ernment	Central	State	Institutional	
1. Indian a) Governme	31It					
b) Private						•
			T T			
International Government			Private	UN	Agencies	
Government						
			1			

Tick appropriately
Sponsor Information :
1 Indian a) Government Central State Institutional
b) Private
2 International Government Private UN Agencies
3 Industry National Multinational
Contact Address of Sponsor:
Total Budget: Who will bear the cost of investigation / implants drugs / contrasts? Patients Project Exempted Other Agencies
Tick appropriately Sponsor Information :
1 Indian a) Government Central State Institutional
b) Private
2 International Government Private UN Agencies
3 Industry National Multinational
Contact Address of Sponsor:
Total Budget: Patients Project Exempted Who will bear the cost of investigation /
implants drugs / contrasts? Other Agencies

Tick appropriately

Sponsor Information :					
1. Indian a)	Government	Central	State	Institutiona	1
b) :	Private				
2. International (Government	Private	UN	l agencies	
3. Industry 1	National	Multination	nal		
J. Mustry 1	vational	Mutimation	141		
Contact Address of Sponsor:					
Total Budget :					
Who will bear the cost of investigues / contrasts?	stigation / implants	1. 4.	Patient 2. Other Age	Project 3.	Exempted
1.Type of Study:					
Participating Centre:	Cross sectional	case control	cohort	Clinical Trial	Review
	Single center	Multi-cent	tric O	thers (Specify)	
2. Status of Review:					
	New		I	Revised	
3. Clinical Trials: Drug /Vaccines/D i. Does	evice/Herbal Ren the study involve u Drug		V		
Indian Systems of Me Alternate System of M	dicine/	Any other	a		
ii. Is it approved a	nd marketed	K & Europe	USA		
iii. Does it involve a ch administration?	ange in use, dosag	e, route of	Yes	No	
If yes, whether DCGI's Permission is obtain		atory authority's	Yes	No	
If yes, Date of permiss			37	N	
iv. Is it an Investigatio If yes, IND No:	nal New Drug?		Yes	No	
a). Investigator's Broch	nure submitted		Yes	No	
b). In vitro studies data			Yes	No	
c). Preclinical Studies of	lone		Yes	No	
d). Clinical Study is : P	hase I Phase	II Phase III	Phase IV	•	

	re you aware if this study/similar study is being done where?	Yes	No
	s, attach details		
4. Brief des justification f	cription of the proposal – Introduction, review of literature for study, methodology describing the potential risks & beautysis and whether it is of national significance with ration	enefits, outco	me measures,
5. Subject se	lection:		
i.	Number of Subjects :		
ii.	Duration of study :		
iii.	Will subjects from both sexes be recruited	Yes	No
iv.	Inclusion / exclusion criteria given	Yes	No
V.	Type of subjects Volunteers P	atients	
vi.	* * H	No derly andicapped	
vii.	Special group subjects Yes		
VII .	(Tick the appropriate boxes) captives institutionalized er students er ar	mployees med crees	
6. Privacy a	nd confidentiality	Ĭ	_
i.	Study involves - Direct Identifiers Indirect Identifiers/coded Completely anonymised/	<u> </u>	
ii.	Confidential handling of data by staff	Yes	No
	logical/ hazardous materials Use of fetal tissue or abortus	Yes	No
ii.	Use of organs or body fluids	Yes	No
iii.	Use of recombinant/gene therapy	Yes	No
•	has Department of Biotechnology (DBT) approval for products been obtained?	Yes	No
iv.	Use of pre-existing/stored/left over samples	Yes	No
v.	Collection for banking/future research	Yes	No

vi. Use of ionizing radiation/radioisotopes	Yes	No
If yes, has Bhaba Atomic Research Centre (BARC) approval for Radioactive Isotopes been obtained?	Yes	No
vii. Use of Infectious/bio hazardous specimens	Yes	No
viii. Proper disposal of material	Yes	No
ix. Will any sample collected from the patients be sent abroad?	Yes	No
If Yes, justify with details of collaborators		
 a) Is the proposal being submitted for clearance from Ye Ministry's Screening Committee (HMSC) for International collaboration? b) Sample will be sent abroad because (Tick appropriate 		
b) Sample will be sent abroad because (Tick appropriate	uux).	
Facility not available in India Facility in India inaccessible Facility available but not being accessed. If so, reasons		
8. Consent: *Written Oral Oral	Audio-v	risual
i. Consent form: (tick the included elements)		
for drug development	_	s
*If written consent is not obtained, give reasons: Who will obtain consent 2 DI/Co DI Nurse/Counselle		
ii. Who will obtain consent? PI/Co-PI Research staff Nurse/Counsellor Any other		
9. Will any advertising be done for recruitment of Subjects?	Yes	No
(posters, flyers, brochure, websites – if so kindly attach a copy)		
10. Risks & Benefits: i. Is the risk reasonable compared to the anticipated benefits to subjects / community / country?	Yes	No
ii. Is there physical / social / psychological risk / discomfort? If Yes, Minimal or no risk More than minimum risk	Yes	No
High risk		

Iii.Is there a benefit a) to the subject ?		
Direct Indirect		
b) Benefit to society		
11. Data Monitoring	Yes	No
i. Is there a data & safety monitoring committee/ Board (DSMB)?		
ii. Is there a plan for reporting of adverse events?	Yes	No
If Yes, reporting is done to:		
Sponsor L Ethics Committee L DSMB		
iii. Is there a plan for interim analysis of data?	Yes	No
vi. Are there plans for storage and maintenance of all trial database?	Yes	No
If Yes, for how long?		
12. Is there compensation for participation? If Yes, Monetary In kind	Yes	No
Specify amount and type:		
13. Is there compensation for injury?	Yes	No
If Yes, by Sponsor by Investigator by any other		
company 14. Do you have conflict of interest?	Yes	No
(financial/nonfinancial)	103	INO
If Yes, specify:		
11 1 00, speed , t		
Conflict of interest for any other	<u> </u> 1	Vec
Conflict of interest for any other	1	Yes No
investigator(s) (if yes, please	12	Yes No Yes
	1 2	No
investigator(s) (if yes, please explain in brief	12	No Yes No
investigator(s) (if yes, please		No Yes
investigator(s) (if yes, please explain in brief 15. Participant Information Sheet	Attached	No Yes No d English version
investigator(s) (if yes, please explain in brief 15. Participant Information Sheet	Attached Certifie	No Yes No d English version d Hindi version
 investigator(s) (if yes, please explain in brief 15. Participant Information Sheet (mark √ if yes) 	Attached Certified version is a	No Yes No d English version d Hindi version ed that Hindi true translation of
investigator(s) (if yes, please explain in brief 15. Participant Information Sheet	Certific version is a	No Yes No d English version d Hindi version ed that Hindi
 investigator(s) (if yes, please explain in brief 15. Participant Information Sheet (mark √ if yes) 16. Participant Informed Consent Form 	Attached Version is a Attached Attached	No Yes No d English version d Hindi version ed that Hindi true translation of d English version d Hindi version
 investigator(s) (if yes, please explain in brief 15. Participant Information Sheet (mark √ if yes) 16. Participant Informed Consent Form 	Attached version is a Attached Attached Certifie	No Yes No d English version d Hindi version ed that Hindi true translation of d English version
 investigator(s) (if yes, please explain in brief 15. Participant Information Sheet (mark √ if yes) 16. Participant Informed Consent Form 	Attached version is a Attached Attached Certified version is a	No Yes No d English version d Hindi version ed that Hindi true translation of d English version d Hindi version ed that Hindi
 investigator(s) (if yes, please explain in brief 15. Participant Information Sheet (mark √ if yes) 16. Participant Informed Consent Form (mark √ if yes) 	Attached version is a Attached Attached Certified version is a (mark (Please enc.)	No Yes No d English version d Hindi version ed that Hindi true translation of d English version d Hindi version ed that Hindi true translation of vif yes, X if no) lose a
 investigator(s) (if yes, please explain in brief 15. Participant Information Sheet (mark √ if yes) 16. Participant Informed Consent Form (mark √ if yes) 	Attached version is a Attached Attached Version is a Certified version is a (mark (Please enc.)	No Yes No d English version d Hindi version ed that Hindi true translation of d English version d Hindi version ed that Hindi true translation of vi fyes, X if no) lose a separate certificate
 investigator(s) (if yes, please explain in brief 15. Participant Information Sheet (mark √ if yes) 16. Participant Informed Consent Form (mark √ if yes) 17. Whether any work on this project has started or not? 	Attached version is a Attached Attached Certified version is a (mark (Please enc.)	No Yes No d English version d Hindi version ed that Hindi true translation of d English version d Hindi version ed that Hindi true translation of vi fyes, X if no) lose a separate certificate
 investigator(s) (if yes, please explain in brief 15. Participant Information Sheet (mark √ if yes) 16. Participant Informed Consent Form (mark √ if yes) 	Attached version is a Attached Attached Version is a Certified version is a (mark (Please enc.)	No Yes No d English version d Hindi version ed that Hindi true translation of d English version d Hindi version ed that Hindi true translation of vi fyes, X if no) lose a separate certificate
 investigator(s) (if yes, please explain in brief 15. Participant Information Sheet (mark √ if yes) 16. Participant Informed Consent Form (mark √ if yes) 17. Whether any work on this project has started or not? 	Attached version is a Attached Attached Version is a Certified version is a (mark (Please enc.)	No Yes No d English version d Hindi version ed that Hindi true translation of d English version d Hindi version ed that Hindi true translation of vi fyes, X if no) lose a separate certificate

Maratha Mandal's NGH Institute of Dental Sciences & Research Centre, Belgaum

Institutional Ethics Committee

Ongoing Approved Research Review Submission Form

- 1. Reference number
- 2. Month / Year of approval
- 3. Number of ongoing review
- 4. Title of the research proposal
- 5. Name of the Principal Investigator (PI) with qualification and designation
- 6. Name of the Co-investigator(s) (Co-PI) with qualification and designation
- 7. Duration of the Project
- 8. Source of funding & financial allocation for the project / trial
- 9. Has subject recruitment begun?
- 10. If subject recruitment has not begin, give reasons and proceed to No:20
- 11. How many subjects have been screened?
- 12. How many subjects have been recruited?
- 13. How many more to be recruited
- 14. Is subject recruitment continuing?
- 15. Are there any 'drop outs'?
- 16. Are subjects still receiving active intervention?
- 17. Have there been any adverse events? If yes, give details
- 18. Have there been any Serious Adverse Events adverse events? If yes, give details.
- 19. Have there been any unanticipated study-related problems?
- 20. Is there any new risk or benefit information? If yes, give details.
- 21. Are there any interim changes to the protocol or consent form? If yes, give details including submission of revised protocol and consent form for approval
- 22. Does the scientific literature indicate changes in knowledge relevant to the conduct of the study?
- 23. List of attachments for review, if any
- 24. Remarks, if any
- 25. Signature of the Principal Investigator with date.

Note: The above information and enclosures should be furnished wherever necessary depending upon the nature of study proposal.

Institute Ethics Committee, MMNGHIDS- Belgaum

Format for *submission of revised/additional documents, protocols and information regarding already approved projects* to be submitted by the Principal Investigator (PI) (Two copies of this form along with the revised documents to be submitted)

1. IEC Reference No:

2. Appr	Approval Date and Number:				
3. Title:	3. Title:				
4. Princ	cipal Investigator:				
5. Purp	ose of this submission:				
6. New	documents being submitted: Pleas	e list the documents being submitted			
along w	rith the differences from the previous	sly approved documents in a tabular form			
as belov	W:				
_					
S. No.	List of Documents being submitted	List the modifications/revisions made from previously approved proposal, wherever applicable			
•					
•					
	•				
•	•				
Place: Date:		Signature PI/Collaborator Name:			

Six monthly progress of Project

Institute Ethics Committee Reference No
Study title:
Name of the Principal Investigator
Designation / Department
Duration of Study
Date of Starting of the Study
Period of Six monthly progress report: fromto
Progress:
Side Effect if any:
Amendments if any:
Discontinuation reasons:
Progress:
Signature of Principal Investigator Date:

PARTICIPANT INFORMATION SHEET (PIS)

The project must be accompanied by the Participant information sheet addressed to the patient or participant or parent/ guardian, in case of minor. While formulating the participant information sheet, the investigator must provide the subjects with the following information in English and Hindi, in a simple layman's language which can be understood by them, in a narrative form, directed to the participant/ LAR, covering all the points:

- 1. Study Title
- 2. Aims and methods of the research study
- 3. Expected duration of participation
- 4. The benefits to be expected from the research to the participant or to others
- 5. Any risk or discomfort to the participant associated with the study
- 6. Maintenance of confidentiality of records
- 7. Provision of free treatment for research related injury
- 8. Compensation of subjects for disability or death resulting from such injury
- 9. Freedom of individual to participate and to withdraw from research at any time without penalty or loss of benefits to which the subject would be entitled otherwise
- 10. Amount of blood sample (quantity in tea spoon full) to be taken
- 11. Costs and source of investigations, disposables, implants and drugs/ contrast media
- 12. Telephone number/ contact number of Principle investigator and Co-Investigator at the top of each page
- 13. In case of a drug trial:
 - a. The chemical name of the drug, date of its manufacturing and batch number must be mentioned
 - b. Initial bioequivalence study of the drug/ references should be provided
- 14. Self-certification should be given that the translation to vernacular language is correct

PARTICPANT INFORMED CONSENT FORM (PICF)

Protocol Study number:	_				
Patient identification number for this study:					
Title of the project:					
Name of Principal investigator:	Tel. No (s)				
The contents of the information sheet dated	mprehend, and I have fully understood the contents.				
The nature and purpose of the study and its potential and other relevant details of the study have been participation is voluntary and that I am free to withd reason, without my medical care or legal right being	explained to me in detail. I understand that my lraw from the study at any time, without giving any				
I understand that the information collected about me of any of my medical notes may be looked at by permission for these individuals to have access to m	responsible individuals from MMNGHIDS. I give				
I agree to take part in the above study.					
(Signatures / Left Thumb Impression)	Date: Place:				
Name of Participant:Son/Daughter/spouse of:					
Complete postal address:					
This is to certify that the above consent has been ob	tained in my presence.				
Signatures of the Principal Investigator	Date: Place:				
1) Witness – 1	2) Witness – 2				
Signature	Signature				
Name:	Name:				
Address: Address:					

NB: Three copies should be made, one each for (1) Patient (2) Researcher (3) Institution

Data Elements for reporting serious adverse events occurring in a clinical trial

1. Patient Details

Initials & other relevant identifier (hospital/OPD record number etc.)* Gender Age and/or date of birth Weight Height

2. Suspected Drug(s)

Generic name of the drug*

Indication(s) for which suspect drug was prescribed or tested Dosage form and strength

Daily dose and regimen (specify units - e.g., mg, ml, mg/kg) Route of administration

Starting date and time of day Stopping date and time, or duration of treatment

3. Other Treatment(s)

Provide the same information for concomitant drugs (including nonprescription /OTC drugs) and non-drug therapies, as for the suspected drug(s).

4. Details of Suspected Adverse Drug Reaction(s)

Full description of reaction(s) including body site and severity, as well as the criterion (or criteria) for regarding the report as serious. In addition to a description of the reported signs and symptoms, whenever possible, describe a specific diagnosis for the reaction.*

Start date (and time) of onset of reaction Stop date (and time) or duration of reaction Dechallenge and rechallenge information Setting (e.g., hospital, out-patient clinic, home, nursing home)

5. Outcome

Information on recovery and any sequelae; results of specific tests and/or treatment that may have been conducted For a fatal outcome, cause of death and a comment on its possible relationship to the suspected reaction; Any post-mortem findings. Other information: anything relevant to facilitate assessment of the case, such as medical history including allergy, drug or alcohol abuse; family history; findings from special investigations etc.

6. Details about the Investigator*

Name

Address

Telephone number

Profession

(specialty)

Date of reporting the event to Licensing Authority:

Date of reporting the event to Ethics Committee overseeing the site:

Signature of the Investigator

*Note: Information marked * must be provided."*

Member Secretary

	Name of the	Qualific	Organiza	Telephon	FAX No.	Email Id	Address
SL	staff	ation	tional	e Number			
No.			Title				
1	Dr Sandeep	BDS/M	Professor	86609630	0831-	zorb@rediffmail	Maratha Mandal's N.G.
	Katti	DS		86	2479323	<u>.com</u>	Halgekar Institute of Dental
							Sciences, Bauxite Road,
							Belgaum

Members:

Sl.N	Name of the	Qualifica	Organizat	Telephone	FAX No.	Email Id	Address
O	staff	tion	ional	Number			
			Title				
1	Dr. Renuka	BDS/M	Prof. &	98441127	0831-	renummdc@gma	Maratha Mandal's N.G.
	Ammanagi	DS	HOD	40	2479323	<u>il.com</u>	Halgekar Institute of Dental
							Sciences, Bauxite Road,
							Belgaum
2	Dr Rjendra	BDS/M	Prof. &	98454723	0831-	rbhallikerimath@	Maratha Mandal's N.G.
	Hallikerimath	DS	HOD	78	2479323	rediffmail.com	Halgekar Institute of Dental
							Sciences, Bauxite Road,
							Belgaum
3	Dr	BDS/M	Prof. &	84489293	0831-	drviju18@yahoo.	Maratha Mandal's N.G.
	Vijayalakshm	DS	HOD	12	2479323	<u>com</u>	Halgekar Institute of Dental
	i. Kotrashetti						Sciences, Bauxite Road,
							Belgaum

4	Dr. Chandrasheka r Yavagal	BDS/M DS	Prof. & HOD	94801328 28	0831- 2479323	dryavagal@gmail .com	Maratha Mandal's N.G. Halgekar Institute of Dental Sciences, Bauxite Road, Belgaum
5	Dr Anuradha Bandiwadekar	BDS/M DS	Reader	94826485 91	0831- 2479323	anuradhabandiwa dekar@gmail.co m	Maratha Mandal's N.G. Halgekar Institute of Dental Sciences, Bauxite Road, Belgaum
6	Dr Chetana Bogar	BDS/Ms.	Research Officer	95359905 08	0831- 2479323	chetnabogar@gm ail.com	Maratha Mandal's N.G. Halgekar Institute of Dental Sciences, Bauxite Road, Belgaum

40

Supporting staff:

1) Mrs. Vaishali Halgekar

Administrative assistant,

Maratha Mandal's N.G. Halgekar Institute of Dental Sciences,

Bauxite Road, Belgaum

Phone: 8861489129

Dr. Ramakant Nayak
Principal

M.M's. N.G. Halgekar Institute of Dental Sciences
& Research Centre, Belagavi-590010.

MMNGHIDS IEC SOP V1/First Copy